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Abstract
Sepsis is a systemic inflammatory response to an infection. The overwhelming
inflammation has many deleterious effects, including cessation of capillary blood flow.
This cessation may lead to organ failure and subsequent death, but the cause of cessation
during sepsis is not fully understood. Ascorbate (reduced vitamin C) has been shown to
restore capillary blood flow by an unknown mechanism. I hypothesized that activation of
both platelets and the coagulation pathway in sepsis contributes to the cessation of
capillary blood flow and that ascorbate protects against cessation by reducing platelet
activation.
Using intravital microscopy in the mouse hindlimb skeletal muscle in vivo, I
observed that sepsis impairs capillary blood flow and increases both adhesion of
platelets/platelet aggregates to the capillary wall and deposition of fibrin plaques in the
same capillaries. Platelet depletion, blocking of P-selectin (a key adhesion molecule),
antithrombin, and eptifibatide (anti-aggregatory agent) all reduced the capillary blood
flow impairment and platelet adhesion. Intravenous bolus injection of ascorbate reduced
platelet adhesion in capillaries, via the endothelial nitric oxide synthase (eNOS) system.
To study any direct effects of ascorbate on platelet function, I used an ex vivo
model (isolated mouse platelets) examining platelet aggregation under septic conditions.
Here, thrombin, ADP, and thromboxane (agents released into the blood during sepsis),
but not lipopolysaccharide (LPS), tumor necrosis factor (TNF) or septic plasma,
increased platelet aggregation and surface P-selectin protein expression. Ascorbate
inhibited the increased aggregation and P-selectin expression.
Next, an in vitro mouse microvascular endothelial cells model was used to study
the effect of ascorbate on platelet-endothelial cell adhesion. LPS and TNF increased
platelet adhesion and P-selectin mRNA expression in endothelial cells. LPS also
increased P-selectin-containing endothelial granule secretion. Ascorbate prevented the
increased adhesion and granule secretion but did not affect mRNA expression.
Thus, I conclude that impairment of blood flow in the septic microvasculature
requires platelets and is reduced by anti-coagulant/anti-aggregatory agents. Ascorbate
prevents platelet-endothelial adhesion and platelet aggregation, partly through reducing
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P-selectin protein expression at the platelet/endothelial cell surface. Thus ascorbate
reduces adhering platelets in septic capillaries leading to restoration of blood flow.
Keywords: Ascorbate, sepsis, capillary blood flow, platelet aggregation/adhesion, Pselectin
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Chapter 1

INTRODUCTION

This thesis focuses on the capillary blood flow impairment during sepsis, the coagulation
system, a potential key component of this impairment, and the protective effect of
ascorbate (a reduced form of vitamin C) against this impairment. The introduction will
provide background information on: i) sepsis, including factors that contribute to the
capillary blood flow impairment, ii) coagulation, including formation of micro-thrombi,
and iii) ascorbate and its possible use as a treatment for sepsis.

1.1

SEPSIS

1.1.1 Clinical significance
Sepsis is the tenth leading cause of mortality in the United States of America (57) and is
the leading cause of mortality in non-coronary intensive care units in North America
(101), with a mortality rate near 40% (75). Despite extensive research, the mortality rate
for sepsis increased between 1995 and 2005 (81). In low-income countries, the mortality
rate is likely higher as treatment is dependent on available intensive care unit services. In
some countries, there has been no improvement in treating sepsis in the last 10 years (11,
69).
Sepsis is a systemic inflammatory response syndrome due to an infection (15, 27).
Patients are considered septic when they have 2 or more of the following features: core
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temperature ≥ 38oC or ≤ 36oC, heart rate ≥90 beats/min, respiratory rate > 20 breaths/min
or partial pressure of carbon dioxide <32 mmHg or mechanical ventilation, and white
blood cell (WBC) counts >12,000/mm3 or <4,000/mm3. ‘Severe sepsis’ is when there is
dysfunction in 2 or more organs and ‘septic shock’ is when hypotension is present (15).
Current treatment focuses on treating the infection and the features (i.e.,
maintaining blood pressure), while treatments for the inflammatory response are
ineffective or only have marginal benefits (27). Despite extensive research and numerous
clinical trials, only one pharmacological treatment reached clinical approval for treatment
of sepsis, activated protein C, and has since been withdrawn from the market for lack of
efficacy (74, 94). The lack of progress in determining effective treatments represents our
limited understanding of the mechanisms involved in the pathophysiology of sepsis.

1.1.2 Pathophysiology of sepsis
On the cellular level, the inflammatory response in sepsis is a result of overwhelming
production of cytokines by the host to defend against an invading pathogen. In the case of
a gram-negative bacterial infection, sepsis is initiated by the endotoxin lipopolysacchride
(LPS), a component of gram negative bacteria. LPS results in the release of cytokines
such as tumour necrosis factor α (TNFα), interleukin-6 (IL-6), and interferon  (IFN) (2,
97) from macrophages and lymphocytes. This process is mediated through toll-like
receptor 4 (90) and proteins of the complement system (125). These cytokines, along
with LPS, further stimulate macrophages, neutrophils, platelets, and endothelial cells to
express adhesion proteins and chemokines as well as produce reactive oxygen species
(ROS) and nitric oxide (NO) (90). The end result of these processes includes many
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serious physiological alterations including a multitude of circulatory dysfunctions such as
hypotension, decreased systemic vascular resistance, impaired oxygen utilization,
maldistribution of blood flow in the microcirculation, impaired capillary blood flow, and
decreased cellular communication along the vascular wall (15, 27, 60, 109, 110, 112).
These dysfunctions eventually progress towards tissue injury and multiple organ failure
(49) (Figure 1.1).

1.1.3 Capillary blood flow impairment
As mentioned, one consequence of systemic inflammation is an impairment of capillary
blood flow. This impairment has been observed and defined as a decrease in perfused
capillaries and an increase in non-perfused capillaries in rat and mouse skeletal muscle
(3, 60, 107, 108). In other words, there is an increase in the percentage of stopped-flow
capillaries during sepsis. A similar impairment of capillary blood flow is evident in other
organs and in septic patients (10, 14). The microvascular dysfunction leads to poor
oxygen transport and tissue hypoxia due to increased oxygen diffusion distances from red
blood cells in capillaries to the mitochondria of surrounding cells (30, 40). Tissue
hypoxia due to this impairment may account for one third of patients who die from organ
failure even when shock is prevented (98, 99). The underlining mechanism of the
capillary blood flow impairment is not yet known.
The impairment of flow is heterogeneous in nature meaning that capillaries in a
capillary unit supplied by a common arteriole and drained by a common venule include
both perfused and stopped-flow capillaries (107). This indicates that the impairment is
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Figure 1.1. A simplified scheme representing the mechanism of LPS-induced sepsis.
LPS from gram negative bacteria enters circulation and stimulates macrophages (M) and
neutrophils (PMN) to release cytokines such as TNF. These cytokines (along with LPS)
activate endothelial cells (ECs), platelets, and white blood cells (WBC) to further produce
cytokines as well as ROS and NO. These mediators, together with the ECs, platelets, and
WBC, cause vascular damage, microthrombosis, and vasodilation potentially leading to
septic shock, multiple organ failure (MOF), and/or death.
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not due to dysfunction of larger blood vessels. Since the microcirculation in skeletal
muscle does not contain precapillary sphincters (31) (i.e., smooth muscle cells encircling
the entrance segment of the capillary) there is no obvious physiological process (e.g.,
constriction and relaxation of sphincters) that could explain this heterogeneous capillary
blood flow. Thus, the stoppage of flow in capillaries seen during sepsis is most likely an
outcome of pathological processes initiated by sepsis.
There are various microvascular dysfunctions in sepsis that could contribute to the
capillary blood flow impairment (Table 1.1, columns 1 and 2, on page 18), including the
plugging of the capillary lumen by adhering leukocytes, stiffened erythrocytes and/or
micro-thrombi containing platelets and fibrin plaques. Leukocytes are known to have
increased adhesion to the endothelium during sepsis (25, 79) and could possibly plug
capillaries. However, leukocytes are located primarily in the lung and liver during sepsis
(80, 82). Accordingly, it was concluded that leukocytes are not responsible for the
impairment in septic rat skeletal muscle (91). Based on this report we predicted that, in
our mouse skeletal muscle model of sepsis, leukocytes may have a minor/negligible role
in the impairment. Erythrocytes have been shown to have decreased deformity during
sepsis (9), and therefore they may contribute to capillary plugging. Platelets become
activated during sepsis, leading to their increased aggregation and adhesion to the
capillary wall (66). Combined with increase fibrin formation (detailed in section 1.2.2),
this would progress to the formation of microthrombi that could block the flow in the
capillary. Since little is known about the mechanism of capillary plugging, this thesis will
focus on investigating the role of platelets and microthombi in the capillary blood flow
impairment
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Clinically, a lowered platelet count in systemic blood correlates with increased
severity of sepsis (77). One possibility is that platelets are ‘trapped’ in the capillaries due
to the formation of microthrombi. It was observed that the blood flow in a single capillary
has intermittent stoppage periods until it ultimately becomes permanently stopped. This
could be explained by the process of ongoing formation and breakdown (thrombolysis) of
thrombi in capillaries during the initial stage of sepsis. The progressing severity of sepsis
eventually tilts the equilibrium towards microthrombi formation leading to the plugging
of capillaries (35).

1.1.4 ROS and sepsis
ROS are highly reactive molecules due to an unpaired electron in their outer orbit. The
main biological radicals include superoxide, hydroxyl and peroxynitrite radicals, and
hydrogen peroxide (non-radical) (41). Superoxide and hydrogen peroxide react with other
molecules until they are eventually converted to water by superoxide, catalase, and the
glutathione peroxidase enzyme system (28). However, when NO levels are high,
superoxide reacts with the NO to form peroxynitrite (96). Peroxynitrite is known to have
toxic effects on cells by interacting with lipids, protein, and DNA (41).
The major vascular source of ROS is NADPH oxidase found in neutrophils,
macrophages, and endothelial cells (43). The superoxide producing NADPH oxidase is
composed of 6 subunits (p22phox, gp91phox, p47phox, p67phox, rac, and p40phox) and
translocates to the plasma membrane upon stimulation to form a catalytically active
oxidase (54) . LPS and imflammatory cytokines are known to stimulate NADPH oxidase,
and thus NADPH oxidase has an important role in the pathophysiology of sepsis (67, 83).
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1.1.4.1 ROS in sepsis
Septic patients often show signs of oxidative stress and decreased levels of the
antioxidant ascorbate, which correlate with lower levels of survival (22, 38). During
sepsis, ROS has been shown to cause endothelial damage and dysfunction (6), increase
the expression of adhesion proteins (124), enhance platelet adhesion and activation, and
promote coagulation (21, 47, 87). Sepsis was shown to increase ROS production in
skeletal muscle in part by NADPH oxidase (123). In particular, LPS+INFγ treatment has
been shown to increase superoxide production in endothelial cells (120). It is important to
note that increased ROS in the septic capillary will cause the conversion of
tetrahydrobiopterin (BH4) to dihydrobiopterin (BH2) (59), limiting the available BH4
needed for proper vascular homeostasis (see section 1.1.5.1).
ROS has been implicated as a potential cause for the sepsis-induced capillary
blood flow impairment. Removal of a major source of ROS by gp91phox (a subunit of
NADPH oxidase) knockout, reduced sepsis-induced capillary blood flow impairment
(107). Furthermore, treatment of septic rodents with the anti-oxidant ascorbate prevented
and reversed the capillary blood flow impairment in septic models (3, 107, 108).

1.1.5 NO and sepsis
Although NO is primarily known as a vasodilator, it is a very important signalling
molecule for vascular homeostasis with effects including inhibition of platelet adhesion
and aggregation (44). Endogenous NO is produced from 3 distinct nitric oxide synthases
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(NOS): neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or NOS2), and
endothelial NOS (eNOS or NOS3).
NO is synthesized by these enzymes in a 2 step oxidation reaction resulting in the
conversion of L-arginine to L-citrulline. This reaction requires oxygen and NADPH as
co-subtrates, the calcium-dependent enzyme calmodulin and the co-factors flavin adenine
dinucleotide, flavin mononuleotide, heme, and BH4. During this reaction, electrons are
passed from the NADPH to the heme in the oxygenase domain with assistance from the
co-factors. This flow of electrons needs to be tightly regulated and if interrupted it will
lead to the production and release of superoxide. This is referred to as the ‘uncoupled’
state of NOS. One such disruption to the flow is when the availability of BH4 becomes
limited (33).

1.1.5.1 NO effects during sepsis
Sepsis is associated with the excessive production of NO as plasma levels of nitrite and
nitrate are elevated (5) in septic patients. This elevation occurs due to increased
expression of iNOS by LPS and inflammatory mediators such as TNF, IL-6, and IFN
(53). The increased NO is responsible for the impaired vascular reactivity and
vasodilation leading to hypotension during sepsis (89).
The sepsis-induced capillary blood flow impairment is not affected by genetic
deletion of each of the 3 NOS isoforms (eNOS, nNOS, or iNOS)(107). This suggests that
the impairment is not due to the overexpression of iNOS or the subsequent changes in
vascular reactivity. As mentioned previously, ascorbate treatment rescued the capillary
blood flow in septic mice. Interestingly, this reversal was not seen in the eNOS-/- mice
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(107). Located in endothelial cells and platelets (93), eNOS generates the majority of
vascular NO under normal conditions (33) and contributes to vascular homeostasis by
regulating vasomotor tone (88). NO also inhibits vascular smooth muscle cell
proliferation (39), and platelet aggregation and adhesion (1). Since, during sepsis, BH4
may be limited (due to conversion to BH2 by ROS), eNOS can become uncoupled from
BH4, leading to reduced NO synthesis and thus a reduction of its local effects.
Furthermore, the uncoupled eNOS produces superoxide, further contributing to the
effects of ROS in the capillary in particular, increasing the formation of peroxynitrite and
subsequent damage caused by this highly reactive molecule. Impaired eNOS function,
combined with other factors, contributes to the impairment of the capillary blood flow
(107).

1.2

COAGULATION

1.2.1 Overview
Coagulation is the process by which thrombi are formed to produce and maintain
vascular homeostasis. It contains both a cellular component (platelets; see section 1.2.1)
and a protein component (fibrin; see section 1.2.2). Thrombus formation is in constant
equilibrium with the breakdown of the clot by fibrinolytic factors (35). Both excessive
(hypercoagulation) and insufficient (hypocoagulation) coagulation will lead to disease
states (26, 35, 35). Thus any alteration to the equilibrium can lead to a pathological state.
The coagulation cascade has 2 separate pathways that ultimately lead to platelet
activation and fibrin formation. The intrinsic or contact pathway begins with exposed
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tissue collagen (normally separated from the blood by endothelial cells forming the wall
of blood vessels) which will directly activate the platelets and provide a site for the
formation of a complex that will eventually convert prothrombin into thrombin. The
extrinsic or tissue factor (TF) pathway begins when the protein, tissue factor, comes in
contact with the blood. TF is normally exposed on cells that are not normally in contact
with the blood such as fibroblast and smooth muscle cells. However endothelial cells and
WBCs can express TF on their surface following stimulation by inflammatory mediators
(63). Tissue factor will bind and activate factor VII to form the tissue factor-factor VIIa
complex. This complex will activate factor X (to factor Xa) that subsequently cleaves
prothrombin into its active form thrombin (95). Thrombin then cleaves fibrinogen to
fibrin as well as activating platelets and endothelial cells(24). Thrombin is one of the
strongest platelet activators in vivo (63).
Septic patients commonly manifest coagulation disorders such as
thrombocytopenia (reduced platelet counts) and disseminated intravascular coagulation
(DIC) (63). This is due to cross-talk between the inflammatory and coagulation pathways.
For example, TNFα can upregulate TF (12). Furthermore, direct stimulation by LPS can
also increase TF on endothelial cells (19). Besides affecting thrombin generation by TF,
inflammation can alter coagulation by reducing the function of the anticoagulation
system. This system includes protein C (degrades coagulation factors Va and VIIIa),
antithrombin (inhibits thrombin), and tissue factor pathway inhibitor (inhibits TF-factor
VIIa complex) (63). Finally, inflammation can disrupt the coagulation system by
impairing the fibrinolytic system (34).
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1.2.2 Platelets
Platelets are fully differentiated anuclear cells formed from megakaryocytes in the bone
marrow. They are approximately 1 – 3 microns in diameter and have a lifespan of 7 days.
They circulate in the blood and contribute to vascular homeostasis. When activated, they
form and strengthen thrombi at the site of vascular damage. Pathological disorders can
occur when platelet function is altered. High counts or overactive platelets will lead to
enhance clotting disorders (e.g., stroke), whereas low counts or inactive platelets will lead
to bleeding complications (50).
Platelets are activated by a variety of agents such as thrombin, adenosine
diphosphate (ADP), thromboxane A2 (TXA), collagen, and serotonin (5HT) (32, 68).
Three major events accompany platelet activation: shape change, granule secretion, and
cell surface integrin activation. Platelets change to a more spherical shape with
pseudopods on its surface. This new shape favours platelet rolling thus increasing
adhesion (58). Platelets secrete 2 types of granules: alpha and dense. Dense granules
contain small molecules (ADP, adenosine triphosphate (ATP), serotonin and calcium)
whereas alpha granules contain pro-coagulatory proteins (P-selectin, fibrinogen,
thrombospondin, von Willebrand factor and others). The release of molecules from these
granules acts as a positive feedback for further platelet activation (32, 68). Activation of
cell surface integrins such as glycoprotein IIb/IIIa (GPIIb/IIIa) contributes to platelet
adhesion and aggregation (85).
Reduced platelet counts (thrombocytopenia) is a common feature during sepsis
(64). However, the cause of this reduction is unclear. Due to cross-talk between the
inflammatory and coagulation pathways, in particular the increased levels of thrombin,
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ADP, TXA, and 5HT (20, 51, 63, 71), platelets can become activated during sepsis
leading to increased aggregation and adhesion to the vascular wall (64, 65, 102). Platelets
can be activated by both endotoxin (LPS) and inflammatory cytokines (126, 127).
Activated platelets can in turn increase the expression of tissue factor on monocytes
(104). Furthermore, ROS will potentiate platelet aggregation (46, 56, 100, 113) and
activated platelets will release ROS (another positive feedback mechanism) (8, 113).

1.2.3 Fibrin
Fibrin is an insoluble fibrous protein that forms 3-dimensional matrix structures that
participate in the formation of a clot. Besides physically supporting the clot, fibrin
triggers signalling events that mediate cellular functions (117). Fibrin matrices form
when thrombin cleaves the insoluble fibrinogen into fibrin monomers that polymerise and
branch to form the fibrin network. The architecture of the fibrin network determines the
structural integrity of the clot (114).
The breakdown of fibrin (fibrinolysis) is also very important for homeostasis. Fibrin is
lysed by the protease plasmin, which is formed by cleavage of the circulating
plasminogen. There are 2 plasminogen activators that facilitate this process: tissue
plasminogen activator (tPA), and urokinase plaminogen activator (uPA). Both of these
enzymes are inhibited by plasminogen activator inhibitor-1 (PAI-1) (42).
Fibrin deposition is a common consequence of sepsis. Inflammatory mediators
activate mononuclear cells and endothelial cells to express tissue factor (63). Moreover,
septic patients have elevated PAI-1 levels (103). Although, levels of tPA are also
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increased, the net effect is antifibrinolytic (103). These 2 points suggest that sepsis
produces the state of fibrin clot formation and stabilization.

1.2.4 Endothelial cells
Endothelial cells line the blood vessel walls, providing a barrier between the vascular
lumen and the surrounding cells. Besides the barrier function of the cells, they also
participate in both the inflammation and coagulation process. Endothelial cells express
various adhesion proteins which participate in the inflammatory response in the
microvasculature (111). Specifically, endothelial cells contain pro-coagulatory factors
such as von Willebrand factor (vWF) and P-selectin in Weibel-Palade bodies that are
exposed to the surface when the cells become ‘activated’. Endothelial cells can be
activated by LPS, inflammatory mediators such as TNF, and thrombin (37, 52, 73).
Also, it is well established that there is endothelial damage and dysfunction during sepsis
resulting in a loss of barrier function including microvascular leak and exposure of the
subendothelial matrix (or basement membrane) (62).

1.2.5 Platelet adhesion, aggregation, and thrombi formation
On the molecular level, there are many proteins that facilitate the adhesion of platelets to
the endothelium, to fibrin, and to other platelets to form micro-thrombi. These include Pselectin (CD62P), platelet endothelial cell adhesion molecule-1 (PECAM), vWF, and
glycoprotein IIb/IIIa (GPIIb/IIIa or integrin IIb3) (85).
P-selectin (CD62P) is a 140 kDa glycoprotein that is found in the alpha granules
in platelets and Weibel-Palade bodies in ECs. Upon stimulation of either cell type, P-
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selectin is exposed on the surface of the cell where it can interact with its counter receptor
P-selectin glycoprotein receptor-1 (PSGL1)(13). PSGL1 is found on both platelets (36)
and ECs (23). Thus, the P-selectin-PSGL1 interaction could occur between plateletendothelium, endothelium-platelet, and platelet-platelet. Once bound, the interaction
between the proteins leads to platelet rolling, adhesion, and aggregation. Furthermore, the
binding can signal other effects such as platelet activation (13, 17).
Adhesion of platelets to the endothelium by PECAM, although possible, does not
occur under physiological conditions and is not the primary function of this protein (118).
vWF participates in platelet adhesion and aggregation by acting as a binding
partner, linking proteins together to cause adhesion. Like P-selectin, vWF is stored in
alpha granules and Weibel-Palade bodies and is released upon stimulation. vWF will
interact with GPIIb/IIIa as well as the platelet integrin GPIb, thus linking 2 platelets
together and initiating platelet aggregation. Furthermore, vWF will bind collagen (a part
of the sub endothelial matrix). Therefore vWF will link platelets to the sub-endothelial
matrix, causing platelet adhesion to the vessel wall (72).
GPIIb/IIIa binds to vWF, fibrinogen or fibrin, fibronectin, and vitronectin. Like
many integrins, GPIIb/IIIa can exist in a low active or high active state depending on its
conformation (85, 92). Found constitutively expressed on the surface of platelets,
GPIIb/IIIa will change conformation to a high active state when activation of the platelet
occurs (68, 92). When in this state, GPIIb/IIIa binds to vWF (causing platelet aggregation
and adhesion), fibrinogen or fibrin (linking the platelet to the clot), and to fibronectin and
vitronectin (i.e., proteins found in the sub-endothelial matrix) to participate in platelet
adhesion.
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All of these processes come together during sepsis, which increases (i)
coagulation, leading to increased platelet activation, (ii) endothelial cell activation and
(iii) fibrin formation (which increases P-selectin expression, vWF release, and GPIIb/IIIa
activation). The resulting binding interactions between platelets, ECs, the subendothelial
matrix, and the fibrin network lead to the formation of microthrombi.

1.3

ASCORBATE

1.3.1 Ascorbate treatment
Ascorbate (reduced vitamin C) is the most abundant water soluble antioxidant. It will
react with most ROS including superoxide and peroxynitrite. After reacting, the ascorbate
radical has a low reactivity due to resonance stabilization of the unpaired electron and
readily dismutates to ascorbate and dehydroascorbic acid (18). Ascorbate can also recycle
other antioxidants, such as -tocopherol (vitamin E) and glutathione from the radical
species (78).
Circulating ascorbate levels are significantly lowered in septic patients and animal
models of sepsis (3, 38). In these models, this is likely due to impairment of cellular
mechanisms of ascorbate production during sepsis (55). In critically ill patients, this
depletion is due to increased requirement for ascorbate (7, 70) caused by increased ROS
levels (115, 116). Reduced ascorbate levels correlate with increased severity and
mortality of septic patients (16, 38, 41).
Clinically, ascorbate, in combination with vitamin E, has been shown to reduce
mortality in critically ill patients in a randomized, double-blind, placebo controlled trial
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(22). Furthermore, ascorbate and vitamin E reduced multiple organ failure and shortened
the ICU stay in patients post trauma or major surgery (84). Finally, an extremely high
dose of ascorbate decreased mortality of severely burned patients (105).
In experimental animal models of sepsis, ascorbate bolus given intravenously has
been shown to improve arteriolar responsiveness, arterial blood pressure, liver function,
capillary blood flow, and survival (3, 107, 108, 121, 122). In particular, ascorbate bolus
prevented the sepsis-induced capillary blood flow impairment when administered at the
onset of sepsis (3). Further, when administered late into sepsis (i.e. when the capillary
blood flow impairment was already present), ascorbate improved capillary blood flow
(107, 108). Finally, ascorbate has been shown to improve survival in a mouse CLP (cecal
ligation and perforation) model when given early (121) and in a mouse FIP (feces
injection into peritoneum) model when given late (107). Table 1.1 (columns 3 and 4)
indicates the protective effects of ascorbate and their poteintial role in the capillary blood
flow impairment during sepsis.

1.3.2 Mechanism of protection by ascorbate
We have recently discovered that the protective effect of ascorbate in sepsis is eNOSdependent. Furthermore, application of exogenous NO, or the eNOS cofactor BH4
directly on the impaired capillaries also reversed the impairment (107). Application of
BH4 was ineffective in eNOS-/- mice indicating that its protective effect is also eNOSdependent (107). As stated previously, BH4 is known to be oxidized by ROS and, when
in this state, is no longer a cofactor for eNOS and thus will ‘uncouple’ from eNOS (59,
61). In this uncoupled state, eNOS produces superoxide instead of NO, effectively
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reducing NO production to the local environment (61) and further increasing ROS due to
the formation of peroxynitrite. Therefore, we propose that ascorbate is readily absorbed
into the endothelial cells (115, 116), where it prevents and reverses the oxidization of
BH4, effectively ‘re-coupling’ to eNOS and thus restoring the local NO production. This
local NO then provides beneficial effects alongside any other effects of ascorbate (Figure
1.2).
NO is known to inhibit platelet aggregation and adhesion thus contributing to the
maintenance of blood flow in the microvasculature. Primarily known to prevent platelet
activation through a cGMP pathway, NO has also been shown prevent this activation by
other pathways. Specifically, NO has been shown to reduce P-selectin expression on ECs
(4) and on platelets (44) thus reducing platelet-endothelium adhesion (44, 45, 76, 86).
Thus ascorbate, through NO, may modulate P-selectin function. Since NO has antiplatelet properties, and platelets are believed to involve in septic capillary plugging, the
restored local NO production will lead to a reduction in the capillary blood flow
impairment.
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Table 1.1. Possible underlying processes/events involved in the sepsis-induced
capillary blood flow impairment, and possible protective effect of ascorbate
treatment (intravenous bolus injection).
Pathophysiological process/

Involvement of process/event in

Effect of ascorbate

Protection by

event during sepsis

capillary blood flow impairment

treatment on process/event

ascorbate ?

Decreased blood pressure (3)

Unlikely

Prevents decrease (3)

None

Increased drainage pressure (49)

Unlikely

No effect

None

Increased WBC adhesion (80)

Likely*

Reduced in vitro (25)

None

Increased RBC stiffening, adhesion (10,29)

Likely

Unknown

Possible

Increased platelet adhesion (67)

Likely

Unknown

Possible

Very likely

Unknown

Possible

Increased EC swelling (47)

Possible

Possibly reduced

Possible

Increased edema (63)

Possible

Unknown

None

Increased microthrombi formation (64)

WBC – white blood cell, RBC – red blood cell, EC – endothelial cell, *unlikely in skeletal
muscle
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Figure 1.2. Mechanism of restored nitric oxide (NO) production by ascorbate during
sepsis. Under normal physiological conditions, local NO is produced from L-arginine (Larg) through the enzyme endothelial nitric oxide synthase (eNOS) with the aide of the
cofactor tetrahydrobiopterin (BH4). During sepsis, increased levels of reactive oxygen
species (ROS), causes the conversion of BH4 to dihydrobiopterin (BH2). BH4 becomes
limited, effectively ‘uncoupling’ from eNOS, which produces superoxide instead of NO.
Treatment with ascorbate will decrease the ROS as well as convert BH2 back to BH4
restoring eNOS function and NO production.
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1.4

RATIONALE, HYPOTHESIS, and OBJECTIVES

1.4.1 Rationale
Despite extensive research, there is no pharmacological therapy for the treatment of
sepsis. This represents a lack of understanding of the complex cellular and molecular
mechanisms that govern the disease. The sepsis-induced capillary blood flow impairment
has been associated with poor prognosis of sepsis and is a possible mechanism for the
multiple organ failure seen in severe sepsis (99). However, the precise mechanisms of
this impairment remain unclear. The impairment is a physical hindrance of blood flow in
the capillary and one of the most likely candidates to cause this hindrance is the
formation of micro-thrombi. To this extent, the roles of platelets and fibrin with regards
to the capillary blood flow impairment have not been investigated.
Over 10 years ago, Armour and coworkers (3) first demonstrated that treatment
with ascorbate had beneficial effects on capillary blood flow during sepsis. Since then,
there have been numerous studies confirming the beneficial effect of ascorbate in sepsis
(3, 106-108, 119, 121, 122). The mechanism of ascorbate’s effect on the capillary blood
flow impairment is unresolved. It is known that the effect of ascorbate is eNOS
dependent, presumably due to the restoration of local NO. NO plays an important role in
the homeostasis of coagulation, and thus any contribution to the capillary blood flow
impairment by the coagulation system (i.e., microthrombi formation), will be altered by
the increased local NO. Further information regarding this will (i) further the
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understanding of the molecular interactions occurring during sepsis, and (ii) encourage
the use of ascorbate as a therapy for septic patients.

1.4.2 Hypotheses
1) Increased platelet adhesion, aggregation and microthrombi formation during
sepsis lead to plugging of capillaries, resulting in capillary blood flow impairment.
2) Ascorbate lowers platelet aggregation and adhesion by decreasing P-selectin
expression, thus improving capillary blood flow during sepsis.

1.4.3 Objectives
1) Determine the effect of sepsis on capillary blood flow and on platelet adhesion
in capillaries of mouse skeletal muscle, and examine the roles of the coagulation system,
ROS and NO in sepsis-induced impairment of capillary blood flow and platelet adhesion.
This objective will be addressed in Chapter 2.
2) Use an ex vivo model to examine i) the effect of sepsis on platelet aggregation
and P-selectin expression and ii) the protection by ascorbate against sepsis-induced
aggregation and P-selectin expression. This objective will be addressed in Chapter 3.
3) Use an in vitro model of microvascular endothelial cells to examine i) the
effect of sepsis on platelet-endothelial cell adhesion and P-selectin expression in
endothelial cells and ii) the protection by ascorbate against sepsis-induced plateletendothelial adhesion and P-selectin expression in endothelial cells. This objective will be
addressed in Chapter 4.
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Chapter 2

Impaired microvascular perfusion in sepsis requires activated coagulation and Pselectin mediated platelet adhesion in capillaries

A version of this chapter has been published previously

Secor D, Li F, Ellis CG, Sharpe MD, Gross PL, Wilson JX and Tyml K. Impaired
microvascular perfusion in sepsis requires activated coagulation and P-selectin-mediated
platelet adhesion in capillaries. Intensive Care Med. 36: 11: 1928-1934, 2010.

42
2.1

INTRODUCTION

Severe sepsis is a systemic inflammatory response in which impaired microvascular
perfusion precipitates organ failure and death (31). Impaired perfusion is seen as
increased number of stopped-flow capillaries and decreased number of perfused
capillaries (13). The impairment increases the diffusion distance for oxygen to
parenchymal cells, leading to tissue hypoxia and organ failure (3, 9). Septic impairment of
capillary blood flow has been visualized in animal organs by intravital microscopy (6, 13)
and in human tissues by orthogonal polarization spectral imaging and sidestream dark-field
imaging (8, 26). Despite the prevalence of capillary flow impairment and its importance in
determining the clinical outcome of sepsis (26), the mechanisms of this impairment are
unknown (19).
Intravascular coagulation in sepsis (2, 7) could be a contributory mechanism.
Inflammatory and coagulation pathways cross-activate (15), including initiation of
coagulation and activation of platelets by lipopolysaccharide (LPS) and inflammatory
cytokines (15, 16), as well as augmentation of inflammation by activated platelets (1, 11,
17, 23, 32). Therefore, sepsis-induced platelet adhesion to capillary endothelium, platelet
aggregates and/or subsequently formed microthrombi could plug capillaries. To our
knowledge, there is no report addressing this possible mechanism. The overall aim of the
present study was to use high-resolution intravital microscopy to examine in “real time”
platelet adhesion and microthrombi formation in septic capillaries. The study had 2 specific
objectives. First, we used treatments known to affect platelet and coagulation functions to
establish the role of these functions in blood flow stoppage in septic capillaries. Second, we
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manipulated the production of reactive oxygen species (ROS) and nitric oxide (NO) in the
microvasculature to determine if the role of platelets in septic blood flow stoppage is
oxidant- and NO-dependent. We discovered that platelet adhesion co-localized with fibrin
deposition in septic capillaries contributes critically to blood flow stoppage.

2.2

METHODS

2.2.1 Animal preparation
We used a fluid resuscitated model of polymicrobial sepsis in mice as described
previously (28, 29). Briefly, male wild type, eNOS-/-, iNOS-/- and gp91phox-/- mice
(C57BL/6, 18 - 27 g body weight, Jackson Laboratory, Bar Harbor, ME) were injected
with feces into the peritoneum (FIP; 50 ml/kg of mixture of saline and feces at 75
mg/ml). For controls, we used naive or sham mice (saline-injected intraperitoneally, 50
ml/kg). Immediately after FIP, mice were injected subcutaneously with 1 ml saline
containing the analgesic buprenorphine (4 μg/ml). Mice were studied by intravital
microscopy at 6-7 h post-FIP because capillary blood flow impairment is established at
this time (29). The experimental protocol was approved by the University of Western
Ontario Council on Animal Care.

2.2.2 Intravital microscopy
Mice were anesthetized with a mixture of ketamine (80 mg/kg) and xylazine (4 mg/kg) at
5.5 h post-FIP (or post-saline injection in shams) and the extensor digitorum longus
(EDL) muscle was prepared for intravital microscopy as a bioassay for capillary blood
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flow impairment (29). To assess impairment, we used an upright microscope (Leitz) and
video-recorded 5 random fields (0.61 x 0.87 mm) per muscle, counted capillaries with
moving red blood cells (CDPER) and stationary red blood cells (CDSTAT) in each field,
normalized counts per mm of a test line drawn across the muscle fibers, averaged CDPER
and CDSTAT from 5 fields (29), and computed the percentage of stopped-flow capillaries
as 100 % x CDSTAT/(CDPER + CDSTAT).
Platelets and fibrin were observed with a high resolution inverted microscope
(Olympus IX81, 20x objective, N.A.= 0.75) yielding 0.35 x 0.47 mm field of view. To
visualize platelets, fluorescent dye rhodamine 6G (0.08 mg/ml saline; Sigma, St. Louis,
MO) was filtered (0.22 μm) and then injected in a 0.05 ml bolus into the penile vein 15
min before visualization. We used fluorescent epi-illumination with TRITC filter and
digital recording to determine adherent platelets in 3 random fields per muscle. Each field
was recorded during two 10 s periods spaced 1 min apart. We verified that objects
fluorescing under TRITC illumination were labeled platelets by viewing with a highresolution 40x objective (N.A.= 0.90) under both TRITC and bright light illumination.
Platelets were counted as adherent if they were stationary during both recording periods
(counts were confirmed by a “blind” observer). In each field, we used bright light
illumination to measure the total length of visible capillaries projected to the surface
plane of the muscle. Platelet adherence was normalized to 1 mm capillary length. Since
rhodamine 6G also labels leukocytes (identified by their large size under bright light
illumination), we similarly measured the occurrence of adherent leukocytes in control and
septic capillaries.
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To visualize fibrin, a 0.1 ml saline bolus containing 200 μg/ml of Alexa 488labeled anti-fibrin antibody (Fibrin II beta clone: T2G1, Accurate Chemical, Westbury,
NY) was injected intravenously 15 min prior to visualization (25). This antibody does not
bind fibrinogen. To assess fibrin deposition in capillaries, we recorded 3 - 6 random
fields for 15 s, measured the total length of capillaries containing fibrin, and expressed it
as the percentage of total capillary length.
In several experiments we determined platelet adhesion specifically in capillaries
with formed fibrin. Here, we first injected the anti-fibrin antibody and then, 20-30 min
later, rhodamine 6G.

2.2.3 Biochemical and blood platelet count analyses
Following intravital microscopy, 0.2 ml blood was collected by carotid artery puncture
and analyzed for lactate (iStat analyzer and CG4+ cartridges, Abbott Laboratories,
Mississauga, ON). Blood was also analyzed for platelet count by diluting 200-fold in
saline, platelets were labelled by rhodamine 6G (0.4 μg/ml) and were counted in a
hemocytometer chamber using an Olympus microscope.

2.2.4 Experimental design: (a) Role of platelet and coagulation functions in
blood flow stoppage
We studied septic mice with lactate above 1 mmol/l at 6-7 h post-FIP. To determine if
platelets are required for blood flow stoppage in septic capillaries, mice were injected
intravenously with platelet-depleting antibody (AIAD31440, purchased from Accurate
Chemical) at 0.5 h post-FIP (5 μl/mouse), P-selectin blocking antibody (2 mg/kg in 0.1
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ml of saline, time 0; clone RB40.34 purchased from BD Biosciences) or control
immunoglobulin (2 mg/kg; purchased from Accurate Chemical). P-selectin is a key
adhesion protein mediating platelet-endothelial interaction (20). To examine the role of
activated coagulation, mice were injected intravenously with antithrombin (250 U/kg, 0.5
h), a glycoprotein IIb/IIIa inhibitor, eptifibatide (180 μg/kg, 6 h), or saline. Thrombin and
glycoprotein IIb/IIIa are required for fibrin and thrombus formation (18). Finally, to
assess the thrombogenic potential of the septic capillary bed at 6 h, we flooded the EDL
muscle with a FeCl3 solution (50 mmol/l in saline, 0.1 ml volume, 5 min) and then
examined capillary blood flow. Topical application of FeCl3 is a conventional approach
to assess thrombosis in microvessels (33).

2.2.5 Experimental design: (b) Roles ROS and NO in platelet adhesion in the
septic capillary bed
To examine the role of ROS, mice were injected intravenously with the antioxidant
ascorbate (10 mg/kg; freshly dissolved, 0 or 6 h) or saline. Alternatively, we used mice
with genetically deleted gp91phox , a subunit of NADPH oxidase (major source of ROS
in septic microvasculature (34)). To assess the role of iNOS-derived NO, we used iNOS-/mice. To examine the role of local NO available near capillaries, we flooded the EDL
muscle with the NOS cofactor tetrahydrobiopterin (BH4; 0.1 μmol/l, in repeated 0.1 ml
bolus applications over 1 h), the NO donor S-nitroso-N-acetylpenicillamine (SNAP; 5
mol/l in one 0.1 ml bolus), decomposed SNAP, or saline. The glass coverslip normally
covering the muscle surface was slightly lifted to permit introduction of the bolus
between the muscle surface and coverslip. To determine if the effects of ascorbate and
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BH4 treatments were eNOS-dependent, ascorbate/BH4 treatments were done in eNOS-/mice.

2.2.6 Statistics
Data are presented as mean ± SE; n indicates the number of mice (one muscle/mouse).
Data were analyzed by Student t-test or ANOVA followed by Bonferroni multiple
comparisons test. Significance was assigned as p < 0.05.

2.3

RESULTS

2.3.1 Role of platelet and coagulation functions in blood flow stoppage
Sepsis markedly increased blood flow stoppage in capillaries in mice (Figure 2.1; control
data in naive and sham-injected mice did not differ, and were therefore pooled here). No
stoppage was seen in arterioles or venules. Sepsis also markedly increased platelet
adherence and fibrin deposition in capillaries (Figure 2.1). We observed single-adhering
platelets and aggregates up to 5 platelets. Platelets preferentially adhered in stopped-flow
capillaries (4.5 ± 1.0, n = 7) rather than in perfused capillaries (0.2 ± 0.1 platelets/mm, n
= 7). The number of adherent leukocytes in capillaries was negligible (0.11  0.04
leukocytes/mm in septic mice; not significantly different from zero in control mice, n =
5). Formed fibrin occurred only in stopped-flow capillaries; none was seen in
arterioles/venules. We also determined platelet adhesion specifically in capillaries with
formed fibrin. Platelet adhesion in these specific septic capillaries was more extensive
(3.6 ± 0.8 platelets/mm, n = 4) than adhesion in any septic capillaries (1.6/mm, Figure
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Figure 2.1. Sepsis increases blood flow stoppage, platelet adhesion and fibrin
deposition in capillaries in mouse skeletal muscle. Sepsis was induced by feces
injection into peritoneum (FIP). Flow stoppage was determined in 18 control and 16
septic mice at 6-7 h, adhesion in 9 control and 7 and septic mice at 7 h, and fibrin
deposition in 2 control and 4 and septic mice at 7 h post-FIP. * Difference from control, p
< 0.05.
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2.1), confirming that septic platelet adhesion and fibrin deposition occurred in the same
capillaries.
Platelet-depleting antibody dramatically lowered serum platelet counts in control
(from 850 ± 50 to 40 ± 20) and septic mice (610 ± 40 to 60 ± 20 x 109/l) (n = 8-13). In
septic mice, the antibody decreased the abundance of stopped-flow capillaries (41 ± 2 to
28 ± 2 %, p< 0.05, n = 16, 12, respectively), implicating platelets in septic impairment of
capillary flow.
P-selectin blockade, antithrombin and eptifibatide significantly reduced platelet
adhesion and blood flow stoppage in septic capillaries (Figure 2.2), indicating that Pselectin and coagulation activation were required for this adhesion/stoppage. Injection of
control immunoglobulin did not affect septic adhesion/stoppage (1.32  0.10
platelets/mm; 41  3 % stopped-flow capillaries, n = 5). Finally, FeCl3 was topically
applied on the EDL surface. Topical application of FeCl3 on microvessels is a
conventional approach to assess the thrombogenetic potential in these microvessels (33).
Fifty micromolar of FeCl3 in a 0.1 ml volume applied for 5 minutes stopped flow more
extensively in septic than control capillaries (Figure 2.3), suggesting that sepsis increased
the propensity of microthrombi formation in capillaries.
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Figure 2.2. Effect of P-selectin blocking antibody, eptifibatide, and antithrombin on
platelet adhesion and blood flow stoppage. Injections of P-selectin blocking antibody at
0.5 h, eptifibatide at 6 h (glycoprotein IIb/IIIa inhibitor), and antithrombin at 0.5 h
inhibited platelet adhesion and blood flow stoppage in capillaries at 6-7 h post-FIP. *
Difference from sepsis, p < 0.05, n = 5-9 for adhesion groups, and 5-16 for stopped-flow
groups.
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Figure 2.3. Sepsis increases thrombosis in capillaries. The thrombosis potential was
tested by flooding the muscle with FeCl3 at 6 h post-FIP. Left panel: * Difference
between post-FeCl3 and pre-FeCl3 percentage of stopped-flow capillaries, p < 0.05, n = 518. Right: Change in stopped-flow percentage = (post-FeCl3 percentage) - (pre-FeCl3
percentage). * Difference from control, p <0.05, n = 5 per group.
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2.3.2 Role of ROS and NO
Prophylactic injection of ascorbate, or gp91phox deletion, prevented platelet adhesion and
flow stoppage in septic capillaries (Figure 2.4). Moreover, delayed injection of ascorbate
reversed septic adhesion/stoppage (Figure 2.5). These latter effects were eNOSdependent, since they were absent in eNOS-/- mice (Figure 2.5). BH4 and NO donor
SNAP at 6-7 h significantly reduced septic platelet adhesion and flow stoppage (Figure
2.6, top). Flooding of the muscle surface with decomposed SNAP or saline did not affect
septic flow stoppage (44 ± 2 and 47 ± 2 % stopped-flow capillaries, n = 7, 3, respectively,
versus 41 ± 2 %, n = 16 in non-flooded septic muscles). The reversal effects of BH4 were
eNOS-dependent, since they were absent in eNOS-/- mice (Figure 2.6). Consistently, the
effects of SNAP did not depend on eNOS (Figure 2.6). eNOS knockout did not affect
blood flow stoppage and platelet adhesion in septic capillaries (Figure 2.5), but iNOS
knockout inhibited platelet adhesion (Figure 2.6, bottom). Flow stoppage in control
gp91phox-/-, eNOS-/- and iNOS-/- mice (12 ± 2, 12 ± 5, and 5 ± 1 % stopped –flow
capillaries, p< 0.05, n = 3, 5, 4, respectively) was not statistically different from that of
control wild type mice (8 ± 1 %, n = 18) (Figure 2.1).
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Figure 2.4. Effect of ascorbate and gp91phox knockout on platelet adhesion and
blood flow stoppage. Ascorbate injection at 0 h and gp91phox knockout prevent platelet
adhesion and blood flow stoppage in capillaries at 6-7 h post-FIP. * Difference from
sepsis wild type (wt) group, p < 0.05, n = 6-7 for adhesion groups, and 5-16 for stoppedflow groups.
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Figure 2.5. Effect of ascorbate on platelet adhesion and blood flow stoppage in wild
type and eNOS knockout mice. Ascorbate injection at 6 h reverses platelet adhesion and
-/-

blood flow stoppage in capillaries at 7 h post-FIP in wild type but not eNOS mice. *
Difference from sepsis group, p < 0.05, n = 6-17 for adhesion groups, and 8-16 for
stopped-flow groups.
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Figure 2.6. Effects of tetrahydrobiopterin (BH4) and the NO donor SNAP on platelet
-/-

adhesion and blood flow stoppage in capillaries of wild type and eNOS mice (top),
and effect of iNOS knockout on adhesion/stoppage (bottom). At 6 h, 0.1 ml boluses of
BH4 (repeated over 1 h period) flooded the muscle surface to determine platelet adhesion
and flow stoppage at 7 h post-FIP. Alternatively, a single 0.1 ml bolus of SNAP flooded
the surface, and platelet adhesion and stoppage were determined 15 min later (when the
temporary SNAP-induced vasodilation had ended). BH4 reversed platelet adhesion and
-/-

flow stoppage in septic capillaries of wild type but not eNOS mice. SNAP reversed
platelet adhesion and flow stoppage in both types of mice. iNOS knockout inhibited
septic platelet adhesion at 6 h post-FIP. * Difference from appropriate sepsis group, p <
0.05, n = 5-10 for adhesion groups, and 5-16 for stopped-flow groups in top row, and 6
and 10 for adhesion, and 6 and 10 for stopped-flow groups at bottom, respectively.
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2.4

DISCUSSION

The present study addressed the mechanism of blood flow stoppage in septic capillaries.
We report for the first time that (i) sepsis markedly increases platelet adhesion, fibrin
deposition and propensity of thrombosis in capillaries, (ii) capillary flow stoppage
requires platelets, P-selectin, and coagulation activation, and (iii) capillary platelet
adhesion can be prevented or reversed by gp91phox and iNOS deficiencies, ascorbate, and
local BH4 and exogenous NO.

2.4.1 Role of platelet and coagulation functions in blood flow stoppage
In the present study, platelets adhered in septic capillaries and venules consistent with the
literature (30). However, unlike in capillaries, adhering platelets in venules were not
associated with fibrin deposition or stopped blood flow, indicating that rheological
findings in larger microvessels cannot be extended to capillaries. In view of negligible
leukocyte adhesion observed in capillaries, we sought leukocyte-independent
mechanism(s) of capillary plugging in sepsis.
Possible mechanisms could be platelet activation, aggregation, and subsequent
critical narrowing/plugging of the capillary lumen by adhering platelets (17, 32), or
plugging by adhering platelets and formed microthrombi within the capillary. LPS and
inflammatory cytokines increase expression of P-selectin and von Willebrand factor on
endothelial cells to initiate platelet adhesion (4, 16). LPS and cytokines also increase
tissue factor expression at the cell membrane of monocytes and endothelial cells (15),
initiating coagulation. The present data are consistent with the mechanism of platelet
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adhesion and microthrombi formation. Sepsis increased platelet adhesion in capillaries,
whereas platelet depletion and blockade of P-selectin significantly reduced septic blood
flow stoppage (Figure 2.2). Sepsis-induced platelet adhesion and fibrin deposition were
seen to co-localize in stopped-flow capillaries, while anticoagulants decreased septic
platelet adhesion and flow stoppage in capillaries (Figures 2.1, 2.2).
In critically ill patients, a 30 % drop in platelet count independently predicts death
(21). In the present study, a comparable 28 % drop occurred in septic mice. Since the life
span of platelets is longer than 6 h (22), we hypothesize that most of this platelet
consumption is due to platelet adhesion in the microcirculation. To estimate how platelet
adhesion in capillaries predicts septic blood flow stoppage, we used the present data to
plot the mean values of stopped-flow capillaries (%) versus values of platelet
adhesion/mm (Figure 2.7). The plot has a significant linear correlation, indicating that
platelet adhesion in capillaries predicts ~ 90 % of capillary blood flow stoppage. If
decreased platelet count were due to platelet adhesion in capillaries, then the 28 % drop
implicates a substantial plugging of the capillary bed (e.g., 40 % plugging in skeletal
muscle).

2.4.2 Role of ROS and NO in septic capillaries
We showed that sepsis increases ROS production in mouse skeletal muscle (35) and that
septic capillary blood flow impairment depends on NADPH oxidase (29). ROS promote
expression of P-selectin at the surface of platelets and endothelial cells, and enhance platelet
adhesion to the endothelium and coagulation (12, 15, 24). Our data are consistent with ROSmediated blood flow stoppage due to enhanced platelet adhesion in capillaries. The
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Figure 2.7. Platelet adhesion in septic capillaries predicts capillary blood flow
impairment. The average values of percent stopped-flow capillaries in experiments of
Figures 2.1, 2.2, 2.4, 2.5 and 2.6 (bottom) were plotted against the corresponding average
values of adherent platelets/mm. In these experiments, no systematic difference existed
between the treatment/concentration of agents in surface and deep capillaries (e.g., agents
were injected intravenously, rather than introduced by flooding of the muscle surface).
Computed line of linear regression has r2 = 0.89 and slope different from 0, p< 0.05.
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antioxidant ascorbate and gp91phox knockout prevented/reversed septic platelet adhesion
and flow stoppage (Figures 2.4, 2.5) (an effect consistent with ascorbate’s ability to
significantly improve septic mouse survival at 24 h) (29, 35).
Recently we proposed that increased ROS level in sepsis oxidizes the eNOS
cofactor BH4, uncouples it from eNOS in platelets and endothelial cells and thus stops
NO production in these cells (29). Because low physiological levels of NO are antiaggregatory and anti-adhesive (24), uncoupled eNOS promotes platelet
adhesion/aggregation and flow cessation in capillaries. The present data are consistent
with this proposed mechanism. BH4 or NO applied locally reversed platelet adhesion and
flow stoppage in septic capillaries (Figure 2.6). Further, the beneficial effects of
ascorbate and BH4 were eNOS-dependent (Figures 2.5, 2.6).
Knockout of iNOS reduced septic platelet adhesion (Figure 2.6, bottom),
suggesting that iNOS-derived NO is pro-adhesive. At first glance, this result contradicts
the beneficial effect of local NO (Figure 2.6, top). To reconcile these observations, we
note that iNOS enzymatic activity is negligible in the mouse skeletal muscle at 6 h of
sepsis (29) and hypothesize that (i) iNOS activity is higher in other septic tissues and (ii)
NO overproduction here could promote platelet adhesion in the skeletal muscle. Excess
NO could react with superoxide, form peroxynitrite (24), and lead to activation/priming
of blood-borne platelets to adhere in tissues. Increased iNOS expression results in
decreased eNOS activity and expression (27) further reducing the local production of
NO. The apparent opposite effects of NO (Figure 2.6) underscore the complex role
NOS/NO may play during sepsis (5, 14).
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2.4.3 Methodological limitations
The use of the platelet-depleting antibody to study the role of platelets in septic blood
flow stoppage was problematic. Both control and septic mice injected with the antibody
were noticeably sicker than their non-injected counterparts (mice hunched in the cage,
had erected fur, and did not respond to tactile stimuli). Further, the antibody significantly
increased (40 %) capillary flow stoppage in control mice. Consistent with reported
increased mortality in mice by platelet-depleting antibody (10), the present deleterious
effects of the antibody on animal health might have obscured the full beneficial effect of
platelet depletion against septic capillary flow stoppage in skeletal muscle.
Finally, the present value of adherent platelets/mm in sepsis may underestimate
the actual platelet adherence, since plugged septic capillaries may not permit plasma flow
and detection of platelets with a fluorescent dye. Capillary obstructions could also limit
the full impact of agents injected at 6 h on platelet adhesion and blood flow stoppage
studied at 7 h.
In conclusion, we demonstrated that polymicrobial sepsis increases platelet
adhesion and fibrin deposition in skeletal muscle capillaries and that septic impairment of
capillary blood flow requires platelet adhesion, P-selectin and activated coagulation.
Since platelet adhesion and capillary flow impairment can be inhibited by the antioxidant
ascorbate and exogenous NO, administration of ascorbate and/or NO donors to attenuate
platelet accumulation in septic capillaries is an important consideration for future
development of novel adjuvant therapies for sepsis.
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Chapter 3

Ascorbate reduces mouse platelet aggregation and surface P-selectin expression
in an ex vivo model of sepsis

A version of this chapter has been published previously
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platelet aggregation and surface P-selectin expression in an ex vivo model of sepsis.
Microcirculation, [ePub ahead of print], 2013.
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3.1

INTRODUCTION

Sepsis is a systemic inflammatory response due to an infection. Sepsis results in
circulatory dysfunction that can lead to multi-organ failure and death (6, 60). An
exaggerated coagulation response contributes to the severity of the disease in the form of
microvascular thrombosis, leading to disseminated intravascular coagulation (DIC) and
organ dysfunction (28). Furthermore, it has been shown that a reduced platelet count in
blood (i.e., an event contributing to DIC) correlates with higher mortality (27, 37).
Adhering platelets and coagulation (fibrin deposition) in capillaries may lead to cessation
of blood flow in these microvessels, an event frequently observed during sepsis (1, 26,
56, 57, Chapter 2). Cessation of flow will result in increased diffusional distance for
oxygen to reach cell mitochondria, leading to tissue hypoxia and organ failure (14, 17).
It is known that septic plasma potentiates platelet activation (22). The resulting
platelet aggregation and platelet-endothelial adhesion may be critical in capillary flow
impairment in sepsis. Platelets can be activated by a large number of agonists including
thrombin, adenosine diphosphate (ADP), thromboxane, serotonin, and collagen (15, 29).
Thromboxane, serotonin, and ADP are subsequently released from activated platelets to
further aggregation (42). Recently, reactive oxygen species (ROS) have been implicated
to modulate platelet function (25). The levels of platelet-activating agonists and the level
of ROS are increased during sepsis (12, 20, 32, 35, 36, 39, 55). The excess of ROS during
sepsis will oxidize tetrahydrobiopterin which is a cofactor for endothelial nitric oxide
synthase (eNOS). When tetrahydrobiopterin is oxidized, eNOS produces superoxide
instead of nitric oxide (NO). Superoxide will interact with NO to form peroxynitrite,
further reducing the bioavailability of NO. NO is an important factor in the homeostasis
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of platelets and is a known inhibitor of platelet activation/adhesion (41). The antioxidant
ascorbate (reduced vitamin C) has been shown to prevent and reverse the oxidation of
tetrahydrobiopterin thus restoring the NO production via eNOS (23, 38).
Clinically, there is no effective pharmacological treatment for sepsis. Current
management strategies aim to increase oxygen delivery to counteract the rising levels of
lactate (13). One possible treatment that has been under investigation is the use of
ascorbate (33). An intravenous bolus of ascorbate has been shown to increase survival of
septic mice as well as to prevent and reverse the capillary blood flow impairment (1).
Ascorbate also inhibits the sepsis-induced increase in adhesion of single platelets and
their aggregates in capillaries (Chapter 2). Although several mechanisms have been
proposed to explain the beneficial effect of ascorbate in the septic microvasculature (55),
the precise mechanism of this effect is unclear. Ascorbate could act directly, because
oxidative stress of the platelet plays an important role in the platelet activation (54), and
also indirectly because it could restore NO production by the aforementioned eNOS
pathway and thus inhibit platelet adhesion/aggregation (55, 56, Chapter 2).
We have recently reported that the treatment of septic mice with a blocking
antibody against P-selectin reduces adhesion of single platelets/aggregates in capillaries
(Chapter 2). P-selectin is a key platelet-endothelium and platelet-platelet adhesion
molecule (5). In our study, it was not possible to determine whether the platelet and/or
endothelial P-selectin are involved in platelet adhesion to capillaries. To address this
issue, the present study employed a simpler ex vivo model of isolated platelets to examine
(i) the effect of sepsis on the platelet surface P-selectin expression, and (ii) the effect of
ascorbate on this expression. We have also reported that the inhibitory effect of ascorbate
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against adhesion of platelet aggregates in septic capillaries was eNOS-dependent
(Chapter 2). However, we could not differentiate whether the endothelial and/or platelet
eNOS were involved. In the present study, we used the ex vivo model to examine the
platelet eNOS involvement. Overall, we hypothesized that the surface P-selectin
expression and aggregability of activated platelets are reduced by ascorbate in an eNOSdependent manner.

3.2

METHODS

3.2.1 Reagents used
Lipopolysaccharide (LPS), tumor necrosis factor alpha (TNF), ADP, N-Nitro-Larginine methyl ester (LNAME), N-Nitro-D-arginine methyl ester (DNAME), S-NitrosoN-acetyl-DL-penicillamine (SNAP), and ascorbate were purchased from Sigma-Aldrich
(St. Louis, MO). U46619, a thromboxane A2 receptor agonist, was purchased from Enzo
Life Sciences (Farmingdale, NY). Serotonin was purchased from Alfa Aesar (Ward Mill,
MA). The phycoerythrin (PE) conjugated P-selectin antibody (clone: Wug.E9) and PE
conjugated IgG control were purchased from Emfret Analytics (Eibelstadt, Germany). A
fluorescein isothiocyanate (FITC) conjugated CD41 antibody was purchased from BD
Pharmingen (Mississauga, ON). Eptifibatide was from Shering-Plough (Kenilworth, NJ).

3.2.2 Experimental design
To investigate the effect of sepsis on platelet aggregation and P-selectin surface
expression ex vivo, we used plasma from septic mice and the conventional septic
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mediators LPS and TNF. We also used platelet-activating agents known to be released
into bloodstream during sepsis, namely thrombin, ADP, serotonin and U46619
(thromboxane A2 analog) (12, 20, 35, 37, 39). The involvement of NOS in the responses
to the activating agents was examined by using the non-selective inhibitor LNAME.

3.2.3 Platelet collection and isolation, and plasma collection.
Experimental protocols were approved by the University of Western Ontario Council on
Animal Care. Wild type C57BL/6 mice (weight: 18-25 g, age: 1.5 - 4 months) were
obtained from Charles River (Sherbrooke, QE) and bred in our animal facility. We
collected platelets from control male mice anaesthetized with ketamine and xylazine
(Chapter 2). Blood was collected via carotid artery puncture into an acid citrate dextrose
solution in a 6:1 blood to solution ratio. Platelets were isolated as described previously
(53). Briefly, platelet rich plasma was collected by centrifuging the whole blood at 120 g
for 8 min. The plasma was then re-spun to remove any collected leukocytes. Finally, the
platelets were pelleted at 735 g for 10 min and resuspended in calcium free Tyrode’s
buffer. Immediately before testing, normal Tyrode’s buffer was added (1:5 ratio) to the
platelet solution.
We also used the blood collection procedure to obtain plasma from septic mice.
Mice were made septic by fecal injection into peritoneum as previously described (56,
Chapter 2). Blood was collected 4 h post fecal injection.

3.2.4 Platelet aggregation
Platelet aggregation was measured using a custom built Born aggregometer (7). Briefly,
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isolated platelets were placed in a specialized cuvette and treated with thrombin at 0.075
U/ml (i.e., the EC50 value from dose-response curve, Figure 3.1) or 0.0375 U/ml, ADP (1
M), U46619 (320 nM), serotonin (10 M), LPS (10 g/ml), or TNF (10 ng/ml) at
effective concentrations published in the literature (3, 19, 30, 48, 58, 62). Some
experimental groups of platelets were treated simultaneously with ascorbate (100 M),
LNAME (5 mM), DNAME (non-functional LNAME analogue, 5 mM), SNAP (1 M),
inactive SNAP (10 M, exposed to room air for at least 24 h), eptifibatide (clinically used
anti-aggregatory agent, 1.8 g/ml), and/or septic plasma (1:1 ratio with normal Tyrode’s
buffer solution with platelets). The platelets were continuously stirred and the light
transmittance was recorded. Aggregation was determined as the change in light
transmittance in the aggregometer from the initial light transmittance reading prior to
adding any platelet-activating agent.

3.2.5 Flow cytometry
Isolated platelets were treated with thrombin (0.0075 - 7.5 U/ml), LPS (10 g/ml), or
TNF (10 ng/ml) for 5 min at room temperature. Some experimental groups of platelets
were treated simultaneously with ascorbate (100 M), LNAME (5 mM), and/or DNAME
(5 mM). Platelets were then incubated with a PE conjugated P-selectin antibody (clone:
Wug.E9) and a FITC conjugated CD41 antibody (platelet specific marker) for 15 min
prior to stopping the experiment by addition of phosphate buffered solution. As a
negative control, a PE conjugated IgG was used. The labeled platelets were then analyzed
with a flow cytometer (Coulter EPICS XL-MCL, Beckman Coulter, Brea, CA, USA).
The percent of total events indicated the number of events that were both P-selectin and
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CD41 positive over the total number of detectable signals within the assigned region of
the scatter plot (forward scatter 70 – 400, side scatter 6 – 60).

3.2.6 Statistical analysis
Data are presented as mean ± SE; n indicates the number of separate platelet isolations.
Blood from one mouse was used for each isolation. Data were analyzed by student t test
or ANOVA followed by Bonferroni multiple comparisons test. Significance was assigned
as p<0.05.
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Figure 3.1. Dose response to thrombin on mouse platelet aggregation ex vivo.
Isolated platelets were treated with thrombin (0.001, 0.0075, 0.075, 0.75, 7.5 units/ml)
and then placed in an aggregometer. Aggregation was defined as the change in light
transmittance normalized to transmittance at time 0 for each experiment. The initial rate
of aggregation is shown as the percentage of the maximum rate (i.e., caused by thrombin)
per experiment. EC50 value is 0.075 units/ml. n = 6 per group.
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3.3

RESULTS

3.3.1 LPS and TNF do not initiate platelet aggregation nor increase Pselectin surface expression
LPS or TNF did not affect platelet aggregation (Figure 3.2). This figure shows a strong
effect of thrombin (0.075 U/ml) used as positive control. The standard error bars
represent the day-to-day variability of the platelet aggregation. LPS did not potentiate the
aggregation caused by thrombin at a sub-threshold concentration of 0.0075 U/ml (i.e.,
initial rates of aggregation were negligible for thrombin at 0.25  0.16 and for
thrombin+LPS at 0.21  0.15 % maximum; n = 5 per group). Furthermore, collected
septic plasma applied for 5 min did not cause aggregation and also it did not potentiate
platelet aggregation caused by thrombin (initial rate of aggregation for septic plasma was
0.01  0.01 and for septic plasma+thrombin (0.0075 U/ml) it was 0.01  0.01 %
maximum; n = 8 per group). Septic plasma applied for 1 h did not cause aggregation and
did not potentiate the effect of thrombin at 0.0075 U/ml (initial rate of aggregation for
septic plasma was 0.01  0.01 and for septic plasma+thrombin it was 0.01  0.01 %
maximum; n = 6 per group).
Using flow cytometry, we measured the P-selectin surface expression on the
platelets after treatment with LPS and TNF. Neither LPS nor TNF increased the Pselectin expression (Figure 3.3). Again, thrombin (0.075 U/ml) was used as positive
control.
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Figure 3.2. LPS and TNFα have no effect on mouse platelet aggregation ex vivo.
Panel a: Isolated platelets were treated with LPS (10 g/ml), TNFα (10 ng/ml), or
thrombin (0.075 units/ml) and were placed in an aggregometer. Aggregation was defined
as the change in light transmittance normalized to transmittance at time 0 for each
experiment. Platelet aggregation was measured over 5 minutes. Panel b: The initial rate
of aggregation is shown as the percentage of the maximum rate (i.e., caused by thrombin)
per experiment. * P < 0.05 compared to control, n = 5 per group.
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Figure 3.3. Effect of LPS, TNF, and thrombin on P-selectin surface expression on
isolated platelets. Isolated platelets treated with LPS (10 g/ml), TNFα (10 ng/ml), or
thrombin (0.075 units/ml) for 20 min were examined for surface P-selectin expression by
flow cytometry. LPS or TNFα had no effect. Thrombin significantly increased P-selectin
surface expression. P-selectin surface expression is represented by percent of events that
were both positive for P-selectin and CD41 (platelet marker). * P < 0.05 compared to
control, n = 5 per group.
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3.3.2 Ascorbate reduces platelet aggregation to thrombin, ADP, and
U46619
Thrombin, ADP, and U46619 (thromboxane A2 analog) caused platelet aggregation as
expected (Figures 3.4 a-f). Serotonin did not initiate aggregation in our model (initial rate
of aggregation was 2.09  1.22 versus 1.54  0.86 % maximum in untreated controls, n =
5 and 8, respectively). Ascorbate inhibited the initial rate of aggregation due to thrombin,
ADP, and U46619 by 44, 20.4, and 51.5 %, respectively (Figure 3.4). In comparison with
ascorbate, eptifibatide similarly inhibited the thrombin-induced aggregation (initial rate
of aggregation was 40.2  4.50 % maximum, n = 6). The inhibition by ascorbate
depended on the concentration of thrombin employed to aggregate platelets. When the
lower concentration was used (i.e., 0.0375 U/ml), ascorbate inhibited aggregation by 74
% (initial rate of aggregation was 25.8  9.3 % compared to thrombin alone, n = 5).
Ascorbate alone had no effect on platelet aggregation (initial rate of aggregation was 2.38
 1.50 versus 1.54  0.86 % maximum in untreated controls; n = 4 and 8, respectively).

3.3.3 Ascorbate reduces the sensitivity of P-selectin surface expression to
thrombin
Since it is difficult to determine the concentration of thrombin found within the septic
microvasculature in vivo and then test the effect of ascorbate at this concentration, we
examined the effect of ascorbate across multiple concentrations of thrombin. Figure 3.5
represents a dose-response of P-selectin surface expression to thrombin and to thrombin
in the presence of ascorbate. Ascorbate caused a significant increase in the EC50 value
from 0.26  0.03 to 0.40  0.04 units/ml (Figure 3.5 insert), indicating that it reduced the
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sensitivity of platelets to thrombin. Platelets treated only with ascorbate had P-selectin
surface levels similar to controls (ascorbate = 1.16  0.86, control = 0.79  0.65 % of
total events detected by flow cytometer, n = 8 per group).

3.3.4 Ascorbate reduces thrombin-induced platelet aggregation
independent of NOS
Figure 3.6 shows that the non-specific NOS inhibitor LNAME did not alter the effect of
ascorbate on platelet aggregation due to thrombin. This indicates that the effect of
ascorbate was not mediated by eNOS in our ex vivo model. Importantly, platelets in this
model had their ability to respond to exogenous NO, because SNAP significantly
inhibited thrombin-induced aggregation. In the thrombin+SNAP group (n= 5) the initial
rate of aggregation was 66.2  6.6 % of the control group (thrombin+inactive SNAP), (n
= 4, p< 0.05). L-NAME had no effect on thrombin-induced aggregation in the absence of
ascorbate (0.075 U thrombin: 2.67  0.15, thrombin + LNAME: 2.65  0.10 units after 5
min of stimulation, n = 3 per group). L-NAME did not alter the effect of ascorbate on
thrombin-induced P-selectin expression (Figure 3.7). EC50 for
thrombin+ascorbate+LNAME was 0.341  0.025 and EC50 for
thrombin+ascorbate+DNAME was 0.339  0.021 units/ml. L-NAME had no effect on
thrombin-induced P-selectin surface expression in the absence of ascorbator (0.075 U
thrombin: 64.8  5.2, thrombin + LNAME: 57.4  8.0 % of total events detected by flow
cytometer, n = 4 per group).
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Figure 3.4. Ascorbate reduces thrombin-, ADP-, and U46619-induced platelet
aggregation. Isolated platelets were treated with thrombin (0.075 units/ml, Panels a and
b), ADP (1 M, Panels c and d) or U46619 (320 nM, Panels e and f) with or without
ascorbate (100 μM) and then placed in an aggregometer. * P < 0.05 compared to
thrombin alone group, n = 5 (Panel b), compared to ADP alone group, n = 6 (Panel d),
and compared to U46619 alone group, n = 5 (Panel f).
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Figure 3.5. Dose response to thrombin and to thrombin plus ascorbate on P-selectin
surface expression on isolated platelets. Isolated platelets were treated for 20 min with
thrombin (0.0075, 0.075, 0.181, 0.375, 0.7, 0.75, 7.5 units/ml), concurrently with or
without ascorbate (100 M), and then they were examined for surface P-selectin
expression by flow cytometry. P-selectin surface expression was represented by the
percent of events that were both positive for P-selectin and CD41 (platelet marker).
Ascorbate significantly increased the EC50 value from 0.26 to 0.40 units/ml (inset). * P <
0.05 compared to thrombin alone, n = 5 per group.
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Figure 3.6. Effect of ascorbate on thrombin-induced platelet aggregation is
independent of platelet NOS. Panel a: Aggregation of isolated platelets treated with
thrombin (0.075 units/ml) alone or concurrently with ascorbate (100 μM) plus LNAME
(5 mM) or ascorbate plus DNAME (5 mM). Panel b: The initial rate of aggregation for
thrombin, thrombin+ascorbate+LNAME and thrombin+ascorbate+DNAME, shown as
the percentage of the maximum rate per experiment. There was no difference between the
thrombin+ascorbate+LNAME and thrombin+ascorbate+DNAME groups. * P < 0.05
compared thrombin alone group, n = 4 per group.
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Figure 3.7. Effect of ascorbate on thrombin-induced P-selectin surface expression on
isolated platelets is independent of platelet NOS. Isolated platelets were treated for 20
min with thrombin, ascorbate, LNAME, and/or DNAME. P-selectin surface expression
was then measured by flow cytometry. There was no difference in EC50 between the
thrombin+ascorbate+LNAME and thrombin+ascorbate+DNAME groups (inset), n= 4 per
group.
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3.4

DISCUSSION

In the present ex-vivo study we found that ascorbate reduced platelet aggregation and Pselectin surface expression on platelets activated with thrombin, ADP and U46619. This
effect of ascorbate was NOS independent. In contrast to these agents, LPS, TNF and
plasma from septic mice did not alter platelet aggregation nor P-selectin surface
expression.
Our findings that LPS does not alter platelet aggregation and expression of Pselectin are consistent with earlier reports (10, 47, 63). However, recent studies have
shown otherwise, namely that LPS enhances thrombin-induced platelet aggregation and
increases P-selectin expression (11, 52, 64). The reason for these discrepancies is unclear.
We suspect that inter-species differences may be important here because our data agree
with the study of Rumbaut and co-workers (47) who also used platelets from mice.
Consistent with previous reports (8, 40), treatment with TNF also did not initiate
aggregation or increased P-selectin expression. Regarding the lack of effect of plasma
from septic mice, it should be noted that the present protocol for plasma collection from
septic mice included an inevitable delay before its application to the platelet-Tyrode
suspension (about a 30 min delay). During this delay the concentration or effectiveness of
these platelet-activating agents might have been minimized (e.g. half-life of thrombin in
plasma is 56 sec (46)), thus explaining the lack of effect of septic plasma on platelet
aggregation or P-selectin surface expression. To our knowledge, there are no reports
addressing the direct effect of septic plasma on this aggregation/expression under similar
ex-vivo experimental conditions.
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There are numerous reports that sepsis increases the plasma levels of thrombin,
ADP, and thromboxane (12, 20, 32, 35, 36, 39, 55). The present data showing that
thrombin, ADP, and thromboxane promote platelet aggregation are consistent with the
literature (15, 29). Furthermore, thrombin-induced P-selectin expression on platelets has
been reported in humans and dogs where the EC50 value was approximately 0.05 units/ml
(21, 44). Our higher EC50 of 0.26 units/ml is most likely due to the differences between
species and experimental protocol used.
The novel finding of this chapter is that ascorbate reduces platelet aggregation and
P-selectin surface expression. Administration of anti-oxidants ebselen, resveratrol and
trolox have also similar effects (31, 54). Pignatelli and coworkers (45) reported that
vitamin C reduces platelet CD40 expression. However, vitamin C had no effect on
platelet aggregation and P-selectin expression in this report. This discrepancy may be due
to the use of human platelets instead of mouse platelets.
We observed that the inhibitory effect of ascorbate was larger against thrombininduced than against ADP-induced platelet aggregation (Figure 3.4). This could be
explained by 2 mechanisms. First, platelets produce ROS when exposed to various
agonists and these ROS augment the aggregation response (18, 24, 49, 61). The various
agonists will produce different amounts of ROS (2, 4, 25). Therefore, the aggregation
response to a particular agonist may be more sensitive to antioxidant treatment than the
response to another agonist. Second, stimulations with various agonists follow different
pathways to activate platelets. The receptors for thrombin and thromboxane are Gq
coupled, leading to the activation of protein kinase C (PKC) whereas the receptor for
ADP is Gi coupled (29). Both antioxidants vitamin E and gallic acid inhibit PKC activity
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in stimulated platelets (9, 16) although vitamin E may have effects that are independent
of its antioxidant ability. Furthermore, PKC activation in platelets increases the
expression of the ascorbate transporter SVCT2, and therefore increases ascorbate levels
in the platelets (50). This would explain the greater inhibition by ascorbate in thrombinand U46619- stimulated platelets as compared with ADP-stimulated.
Since P-selectin plays a role in both aggregation and platelet-endothelial
adhesion, reducing P-selectin expression/activity would decrease the formation of
microthrombi, leading to reduced capillary plugging. In the previous chapter, we found
that blocking P-selectin reduces the capillary blood flow impairment (Chapter 2). The
ability of ascorbate to reduce the surface expression of P-selectin on platelets may be one
of the mechanisms by which ascorbate reduces the plugging of capillaries.
Our data suggest that, despite the ability of platelets to respond to exogenous NO,
the effect of ascorbate on thrombin-induced platelet aggregation and P-selectin surface
expression is independent of platelet-derived NO. Others have reported that plateletderived NO may only have a minor role in aggregation and P-selectin surface expression
and have indicated that non-platelet sources of NO within the microvasculature may still
have an important inhibitory role in platelet function (43, 51, 59).
The effect of ascorbate in vivo has been shown to be eNOS-dependent through a
mechanism that restores eNOS function during sepsis (23, 55, 56, Chapter 2). The
restored eNOS produces NO that could reduce platelet aggregation in 2 ways. First, NO
reduces platelet activation by the classical cyclic GMP pathway (41). Second, NO
reduces platelet adhesion by reducing P-selectin surface expression via a reduction in
granule secretion. This second pathway includes the nitrosylation of N-ethylmaleimide
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sensitive factor (NSF) which is necessary for proper granule docking to the plasma
membrane (34). Nitrosylated NSF has a diminished function leading to reduced granular
exocytosis and reduced P-selectin surface expression. Our data show that ascorbate works
independently of platelet-derived NOS and imply that ascorbate could reduce platelet
adhesion/aggregation in the absence of restored eNOS function within the
microvasculature. Thus, in the context of plugging of septic capillaries, the inhibition of
platelet aggregation directly by ascorbate may not be enough to fully restore capillary
blood flow. We propose that, in addition to the reduced adhesion/aggregation caused
directly by ascorbate, NO-derived from non-platelet sources (e.g., endothelial eNOS)
may also be required for the full in vivo effect of ascorbate.
Although the inhibitory effect of ascorbate seemed modest (Figures 3.4 and 3.5),
this finding might have reflected the particular conditions of our model. The conditions
were pro-aggregatory with thrombin at 0.075 U/ml, since the anti-aggregatory agent
eptifibatide inhibited aggregation to a similar modest degree as ascorbate (44%
inhibition). Using a lower concentration of thrombin at 0.0375 U/ml, ascorbate inhibited
aggregation more robustly (74% inhibition). Furthermore, the present conditions did not
exclude the effect of endogenous ascorbate remaining in the platelets after isolation. This
remaining ascorbate could have masked the true difference between the control untreated
and ascorbate-treated aggregation of platelets.
In conclusion, we used an ex vivo model of sepsis in mice to demonstrate that
ascorbate (i) reduces platelet aggregation stimulated by thrombin, ADP, and U46619, and
(ii) lowers platelet surface P-selectin expression induced by thrombin, in NOSindependent manner. The ability of ascorbate to inhibit platelet P-selectin expression and
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platelet aggregation could be an important mechanism by which ascorbate inhibits
capillary plugging. Further studies are needed to determine if this inhibition of platelet
aggregation/plugging reduces the organ dysfunction occurring during sepsis.
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Chapter 4

Ascorbate reduces P-selectin mediated platelet-endothelial adhesion in an in vitro
model of sepsis via reduced endothelial granule secretion

A version of this chapter has been submitted to Microcirculation
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4.1

INTRODUCTION

Sepsis is the tenth leading cause of mortality in the US (19) with a mortality rate near
40% (25). Circulatory dysfunctions including cessation of blood flow in septic capillaries
can lead to multiple organ failure (6, 38). Contributing to the capillary blood flow
impairment is increased platelet adhesion and fibrin deposition in the capillary suggesting
the formation of microthrombi (Chapter 2). This could explain the reduced platelet counts
seen in septic patients which correlate with increased mortality (27). The cessation of
capillary blood flow leads to increased diffusional distance for oxygen to reach cell
mitochondria, tissue hypoxia and organ failure (10, 14).
Enhanced coagulation contributes to the severity of sepsis resulting in
microvascular thrombosis and disseminated intravascular coagulation (DIC, (20)). During
sepsis, increased platelet-endothelial adhesion may be critical in capillary flow
impairment (Chapter 2). P-selectin is a key platelet-endothelium adhesion molecule (4) as
inhibition of P-selectin results in decreased platelet adhesion in the septic capillary.
Inhibition also prevents the cessation of capillary blood flow (Chapter 2). P-selectin is
stored in Weibel-Palade bodies in endothelial cells and, upon stimulation, it is expressed
at the surface of the cell where it can facilitate platelet adhesion through binding its
counter receptor P-selectin glycoprotein ligand-1 (PSGL1) (23). Reactive oxygen species
have also been implicated in the capillary blood flow impairment as sepsis increases the
level of ROS (21, 36). ROS have been shown to modulate platelet function by enhancing
platelet activation (18) and indirectly, by altering endothelial function (3). Furthermore,
ROS can reduce local nitric oxide production by oxidizing the eNOS cofactor BH4. When
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BH4 is oxidized, eNOS production of nitric oxide (NO) is reduced. NO is an important
factor in the homeostasis of the microcirculation and is a known inhibitor of platelet
activation/adhesion (30). Furthermore, NO can prevent expression of P-selectin (2), and it
can inhibit P-selectin surface expression by reducing the exocytosis of the Weibel-Palade
bodies in endothelial cells (24). The antioxidant ascorbate (reduced vitamin C) prevents
and reverses the oxidation of BH4 thus restoring local NO production via eNOS (16, 29).
Clinically, there is no effective pharmacological treatment for the systemic
inflammation component of sepsis. Ascorbate has been under investigation as a possible
treatment (22). An intravenous bolus of ascorbate has been shown to prevent and reverse
the cessation of blood flow in septic capillaries as well as increase survival of septic mice
(1, 37). Sepsis-induced increase in adhesion of single platelets and their aggregates in
capillaries are also inhibited by ascorbate treatment (Chapter 2). Although several
mechanisms have been proposed to explain the beneficial effect of ascorbate in the septic
microvasculature (36), the precise mechanism of this effect is unclear.
Our recent study showed that ascorbate could reduce platelet adhesion during
sepsis as well as improve capillary blood flow (Chapter 2). However, it was not possible
to determine if ascorbate was acting directly on the platelet adhesion or that the reduced
platelet adhesion was a consequence of other effects of ascorbate. To address this issue,
the present study employed a simple in vitro platelet-endothelial cell adhesion assay. This
in vitro model could determine (i) the effect of sepsis on the endothelial P-selectin
expression, and (ii) the effect of ascorbate on this expression. We hypothesized that
sepsis-induced platelet-endothelial adhesion and endothelial P-selectin genomic
expression and surface expression are reduced by ascorbate.
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4.2

METHODS

4.2.1 Reagents used
Lipopolysacchride (LPS), tumor necrosis factor alpha (TNF), calcein-AM, protease
inhibitor cocktail, Superscript II, and ascorbate were purchased from Sigma-Aldrich (St.
Louis, MO). The phycoerythrin (PE) conjugated P-selectin antibody (clone: Wug.E9) and
PE conjugated IgG control were purchased from Emfret Analytics (Eibelstadt, Germany).
A P-selectin blocking antibody (clone: RB40.34) and a rat IgG1 lambda isotype control
were purchased from BD Pharminogen (Mississauga, ON). TRIZOL was purchased from
Invitrogen (Burlington, ON). A horse radish peroxidase (HRP) tagged anti-rat IgG
antibody was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA).
A GAPDH antibody and a HRP anti-rabbit IgG antibody were purchased from Cell
Signalling Technology (Danvers, MA). Quantifast SYBR Green master mix was
purchased from Qiagen (Mississauga, ON).

4.2.2 Endothelial cell harvest and culture
All experimental protocols were approved by the University of Western Ontario Council
on Animal Care. Skeletal muscle microvascular endothelial cells were harvested from
wild type (C57BL/6) mice and isolated as performed previously in our lab (5, 41).
Briefly, skeletal muscle from the hind limb of mice was collected and digested. The
digest was plated and grown to confluency. Endothelial cells were isolated by lectin
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coated magnetic beads. Cells were cultured to confluence and cell type was confirmed by
immunocytochemistry, checking for the endothelial marker von Willebrand factor. To
model sepsis, endothelial cells were treated with LPS (10 g/ml) or TNF (10 ng/ml) for
1h. Ascorbate (100 µM) was applied to cells as a pre-treatment 4 h prior to LPS or TNF
treatment. In some experiments, a P-selectin blocking antibody (clone: RB40.34, 1:1000)
or a control IgG was added cells concurrently with LPS or TNF.

4.2.3 Platelet collection and isolation
Blood (600 l) was collected from anaesthetized naive male mice via carotid artery
puncture into a vial containing 100 l of acid citrate dextrose solution. Platelets were
isolated by the method describe by Singer et al (32). Briefly, platelet rich plasma was
collected by centrifuging the whole blood at 120 g for 8 min. The plasma was then respun to remove any collected leukocytes. Finally the platelets were pelleted at 735 g for
10 min and resuspended in phosphate buffer solution (PBS).

4.2.4 In vitro adhesion model to mimic the platelet-endothelial cell
interaction
To visualize platelets with fluorescence microscopy, isolated platelets were incubated
with 8 M calcein-AM for 10 minutes. The platelets were pelleted at 735 g for 10 min to
remove excess calcein-AM and resuspended in fresh PBS. Following endothelial cell
treatment, ~3 x 106 platelets were added to the a confluent monolayer of 0.25 x 106
endothelial cells and co-incubated under static conditions for 1h, and then washed. The
remaining platelets adhering to the endothelial cells were visualized with a Zeiss
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fluorescence microscope using a 20 x magnification objective. Labelled platelets were
then counted in the entire area of the microscopic field of view (0.43 mm x 0.32 mm).
Each treatment group was done in triplicate and 5 arbitrary microscopic fields of view
(chosen blindly) were used per replicate. Counts of attached platelets were repeated by a
separate individual blinded to the conditions.

4.2.5 Septic mouse model
Male mice were anaesthetized with an intraperitoneal (i.p.) injection of a mixture of
ketamine (80 mg/kg) and xylazine (4 mg/kg). Sepsis was induced by feces injected into
peritoneum (FIP) method previously described by our lab (37). Briefly, mice were given
an i.p. injection of 50 ml/kg volume of saline containing 75 mg/ml of feces. Control
(sham) mice received sterile saline i.p. injection 50 ml/kg. Both FIP and sham mice were
given 1 ml of saline containing 4g/ml buprenophine sub-cutaneously, providing fluid
resuscitation and analgesics.

4.2.6 P-selectin and PSGL1 mRNA expression in cultured endothelial cells
and skeletal muscle homogenates
P-selectin and PSGL1 mRNA were measured by real time qPCR. After treatment, mRNA
from the endothelial cells was collected by TRIZOL according to the manufacturer’s
instructions. Hindlimb skeletal muscle was collected from sham and septic mice at 7 h
post-FIP. Prior to this, septic mice were injected intravenously (penile vein) with 1 ml of
sterile saline or with 1 ml saline containing ascorbate (10 mg/kg) at 6 h (i.e., when
capillary plugging is prevalent (37)). Similarly, sham mice were injected with saline at 6
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h. The muscle was homogenized and mRNA was collected by TRIZOL. mRNA was then
reversed transcribe to cDNA by Superscript II. We used qPCR to determine the mRNA
expression levels of P-selectin (primers: forward 5’-GTCCACGGAGAGTTTGGTGT-3’
and reverse 5’-AAGTGGTGTTCGGACCAAAG-3’) and PSGL1 (primers: forward 5’CTTCCTTGTGCTGCTGACCAT-3’ and reverse 5’TCAGGGTCCTCAAAATCGTCATC-3’) and used β-actin (primers: forward 5’TCGTGGGCCGCTCTAGGCACCA-3’ and reverse 5’GTTGGCCTTAGGGTTCAGGGGGG-3’) as our reference gene. The qPCR was carried
out using Quantifast SYBR Green master mix on a Mini-opticon cycler (Bio-Rad,
Mississauga, ON). We used the following cycling protocol: 95°C for 5 min and then 40
cycles of 95°C for 10 s, 60°C for 30 s and 80°C for 30 s. SYBR green fluorescence was
acquired at 80°C in each amplification cycle. Subsequently a melt curve was generated,
starting at 60°C and taking measurements every 0.2°C until 95°C was reached.

4.2.7 Von Willebrand factor (vWF) ELISA
The purpose of this procedure was to assess indirectly P-selectin protein expression at the
endothelial cell surface. Originally, we carried out pilot experiments using
immunocytochemistry and flow cytometry to detect P-selectin. Unfortunately, for
unknown reasons these procedures failed to detect P-selectin under any experimental
conditions. For this reason we have used the vWF ELISA as a surrogate measure for Pselectin surface protein detection. P-selectin is contained together with vWF in WeibelPalade granules under the surface of endothelial cells. Exocytosis of these granules
delivers to the surface both vWF and P-selectin (23).
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Endothelial cells grown to confluence were treated with dialyzed serum medium
with or without ascorbate (100 M) for 4 h. The medium was replaced by fresh medium
without ascorbate and the cells were treated with LPS (10 g/ml) or TNF (10 ng/ml) for
1 h. The cell culture media after the endothelial cell treatments was collected and
measured for von Willebrand factor using a commercially available ELISA kit (Cusabio,
Wuhan, China).

4.2.8 Western blots
Hindlimb extensor digitorum longus skeletal muscle was collected and homogenized in
SDS lysis buffer with protease inhibitor cocktail. The collected protein was run on an
acrylamide gel and transferred to a PVDF membrane. The membrane was probed with a
P-selectin antibody (Clone: Wug.9, at 1:1000) and a HRP tagged anti-rat IgG secondary
antibody (1:5000). To control for protein loading, the membrane was also probed with a
GAPDH antibody (Clone: 14C10, 1:1000) followed by a HRP anti-rabbit IgG secondary
antibody (1:2000).

4.2.9 Statistical analysis
Data are represented as mean  standard error and n represents the number of mice or
separate cell culture experiments where cells were harvested from at least 3 mice. Data
were analyzed by one-way ANOVA followed by Bonferroni comparison. P values less
than 0.05 were considered significant.
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4.3

RESULTS

4.3.1 Ascorbate prevents increased platelet-endothelial cell adhesion in an
in vitro model of sepsis
Both LPS and TNF increased platelet-endothelial cell adhesion under static conditions
(Figures 4.1, 4.2). LPS or TNF-induced increase in adhesion was prevented by blocking
P-selectin (Figure 4.1). The control IgG had no effect (LPS-induced platelet adhesion
with control IgG and TNF-induced platelet adhesion with control IgG were 2.4  0.7
and 2.5  0.9 fold, respectively, over vehicle treated control cells with control IgG, n = 3
per group). Pretreatment of endothelial cells with ascorbate prevented both the LPSinduced and TNF-induced increases in platelet-endothelial cell adhesion (Figure 4.2).
Ascorbate has no effect in vehicle treated cells.

4.3.2 LPS and TNF increase P-selectin mRNA expression but not PSGL1
mRNA
LPS and TNF increased P-selectin mRNA 3 and 4 fold, respectively, in endothelial
cells. However, pre-treatment of the endothelial cells with ascorbate did not affect this
increase (Figure 4.3). Ascorbate has no effect in vehicle treated cells. LPS or TNF
treatments did not alter PSGL1 mRNA (Figure 4.4).
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Figure 4.1. Effect of P-selectin block on LPS or TNFα treated endothelial cellplatelet adhesion. Endothelial cells treated with LPS or TNFα for 1 h were co-incubated
with untreated platelets for 1 h, washed, and adherent platelets were counted by
fluorescence microscopy. A separate group of cells was co-treated with ascorbate a Pselectin blocking antibody during the TNFα treatment. LPS or TNFα treatment
significantly increased the endothelial cell-platelet adhesion. P-selectin block prevented
this increased adhesion. (*significantly different from control untreated group,
#significantly different from control group with the same treatment, p < 0.05, n = 5).
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Figure 4.2. Effect of ascorbate on LPS or TNFα treated endothelial cell-platelet
adhesion. Endothelial cells treated with LPS or TNFα for 1 h were co-incubated with
untreated platelets for 1 h, washed, and adherent platelets were counted by fluorescence
microscopy. A separate group of cells was pretreated for 4 h with ascorbate prior to
LPS/TNFα treatment. LPS or TNFα treatments significantly increased the endothelial
cell-platelet adhesion. Ascorbate prevented this increased adhesion. (*significantly
different from control untreated group, #significantly different from control group with
the same treatment, p < 0.05, n = 5 -8).
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Figure 4.3. Effect of ascorbate on P-selectin mRNA expression in LPS or TNFα
treated endothelial cells. Endothelial cells treated with LPS or TNFα for 1 h were
assayed for P-selectin mRNA expression by real time qPCR. A separate group of cells
was pretreated for 4 h with ascorbate prior to LPS/TNFα treatment. LPS or TNFα
treatments significantly increased P-selectin mRNA. Ascorbate did not affect this
increased expression. (*significantly different from control untreated group, p < 0.05, n =
6 - 7).
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Figure 4.4. Effect of ascorbate on P-selectin glycoprotein ligand-1 (PSGL1) mRNA
expression in LPS or TNFα treated endothelial cells. Endothelial cells treated with
LPS or TNFα for 1 h were assayed for PSGL1 mRNA expression by real time qPCR. A
separate group of cells was pretreated for 4 h with ascorbate prior to LPS/TNFα
treatment. LPS and TNFα did not affect PSGL1 mRNA. (Means are not significantly
different, n = 6 - 7).
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4.3.3 Ascorbate reduces vWF release in LPS treated endothelial cells
LPS but not TNF treatment increased vWF granular secretion from endothelial cells
(Figure 4.5). Ascorbate pre-treatment prevented the LPS-induced vWF release. Ascorbate
showed no effect in vehicle treated cells. Fold change over the vehicle treated control
cells was used due to large variability in the day-to-day experimental data (range of vWF
protein amount in vehicle treated control cells: 0.2 – 5.5 ng/ml).

4.3.4 Sepsis increases expression of P-selectin mRNA but not protein in
muscle homogenates
Muscle homogenates from septic mice at 7 h has a 7 fold higher P-selectin mRNA
compared to sham mice (Figure 4.6). However, Figure 7 shows that there was no
difference in P-selectin protein content between the septic and sham mice homogenates.
Ascorbate injected at 6 h did not affect either the mRNA or protein when compared to the
saline treated control group (Figures 4.6, 4.7).
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Figure 4.5. Effect of ascorbate on endothelial cell granule secretion. Media from
endothelial cells treated with LPS or TNFα for 1 h was collected and assayed for von
Willebrand factor (vWF) expression by ELISA. A separate group of cells was pretreated
for 4 h with ascorbate prior to LPS/TNFα treatment. LPS but not TNF increased vWF
release from endothelial cells. Ascorbate prevented this increased vWF release.
(*significantly different from control untreated group, p < 0.05, n = 5).
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Figure 4.6. Effect of ascorbate on P-selectin mRNA expression in septic mice. At 6 h
after sham injection or feces injection into peritoneum (FIP, model of sepsis), mice were
given an i.v. bolus of saline or ascorbate. At 7 h post-FIP, hindlimb muscle was collected,
homogenized, and analyzed for P-selectin mRNA by real time qPCR. Sepsis increased Pselectin mRNA expression. Ascorbate did not affect this increase. (* significantly
different from sham, p < 0.05, n = 9-13).
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Figure 4.7. Effect of ascorbate on P-selectin protein expression in septic mice. At 6 h
after sham or FIP injection, mice were given an i.v. bolus of saline or ascorbate. At 7 h
post-FIP, hindlimb muscle was collected, homogenized, and analyzed for P-selectin
protein by western blot. A) Shows a representative blot. B) densitometry ratio of the Pselectin:GAPDH signal. Data is displayed as the fold change when compared to the sham
mice. (Means are not significantly different, n = 6).
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4.4

DISCUSSION

In the present study we found that ascorbate reduced platelet adhesion to endothelial cells
stimulated by LPS or TNF. Ascorbate reduced vWF granular secretion from endothelial
cells activated by LPS. On the other hand, ascorbate did not affect P-selectin mRNA
expression in LPS or TNF-stimulated endothelial cells and in skeletal muscle
homogenates from septic mice.
Sepsis has been observed to induce platelet adhesion to the capillary wall in vivo
(Chapter 2). Our present in vitro model successfully mimicked this observation. Both
LPS and TNF have previously been shown to increase platelet-endothelial cell adhesion
(17, 42). In our model, this increased adhesion was P-selectin dependent as blockage of
P-selectin via an antibody prevented stimulated adhesion. We interpret these observations
to indicate that the P-selectin played a direct role in the observed adhesion. However,
since P-selectin-PSGL1 binding can produce further signalling that also leads to adhesion
involving other adhesion proteins (4), the role of P-selectin in the observed adhesion
could also be indirect.
We previously reported that ascorbate reduces platelet adhesion in septic
capillaries (Chapter 2). However, to our knowledge, ascorbate has not been tested in an in
vitro assay to probe for the mechanism of this reduction. Previous reports have shown
that other antioxidants namely vitamin E and quercetin, can reduce platelet-endothelial
adhesion in vitro (11, 34). Szuwart and co-workers (34) found that the inhibitory effect of
vitamin E on platelet adhesion was seen in platelet rich plasma and not in isolated
platelets. Since only the endothelial cells received the treatments in the present in vitro
model, activation of only these cells was responsible for the changes in the platelet-
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endothelial adhesion. Therefore we propose that the LPS or TNF stimulus causes an
increase in P-selectin expression in the endothelial cells leading to the increased
adhesion.
LPS or TNF increased P-selectin mRNA expression in our endothelial model
which is consistent with other reports (13, 33). However, treatment of the endothelial
cells with ascorbate did not affect this expression. Our results disagree with a previous
report that the antioxidant nebivolol inhibits P-selectin mRNA expression on human
macrovascular endothelial cells stimulated with oxidative low density lipoprotein (12).
The difference could be explained by the use of a different stimuli, species, or cell type.
Inflammatory mediators do not affect PSGL1 mRNA expression (9), which agrees with
our present data showing no effect of TNF or LPS on PSGL1 mRNA in our in vitro
model.
Granular secretion measured by vWF release was used as a surrogate biomarker
for P-selectin surface expression. LPS but not TNF increased vWF release from
endothelial cells (Figure 4.5). This, too, is consistent with the current literature. LPS has
been shown to increase vWF release (28) as well as increase P-selectin surface
expression (7) whereas TNF failed to affect vWF secretion (31) and P-selectin surface
expression (7). This suggests that LPS and TNF increase platelet-endothelial adhesion
by different mechanisms. Here we show for the first time that ascorbate can inhibit vWF
release from murine microvascular endothelial cells and thus reduce P-selectin surface
expression. Wang and coworkers (39) showed similar results with the antioxidant genipin
on thrombin stimulated cells, NOS dependently. Likewise, other studies have shown that
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antioxidants reduce P-selectin surface expression caused by thrombin (35) or hypoxia/reoxygenation (15) in human umbilical vein endothelial cells.
In our model, ascorbate could prevent LPS-stimulated granular secretion by
restoring eNOS function. Proper Weibel-Palade body exocytosis requires Nethylmaleimide-sensitive factor (NSF) regulating membrane fusion (26). When
nitrosylated by NO, NSF has reduced function and thus lowers granule secretion (26).
Therefore, ascorbate could restore local NO production, nitrosylate NSF, and
subsequently reduce Weibel-Palade body exocytosis including P-selectin surface
expression. The effect of ascorbate on TNF induced platelet-endothelial adhesion is
unclear. TNF did not increase vWF release and thus did not affect P-selectin surface
expression on endothelial cells. However, TNF-induced platelet adhesion was prevented
by blocking endothelial P-selectin.
Although P-selectin mRNA was increased in septic murine muscle tissue, there
was no change in the protein expression when assessed by immunoblot (Figure 4.7). The
apparent discrepancy between mRNA and protein data could be explained by the fact that
the mRNA from the muscle homogenates comes exclusively from the endothelial cells
whereas the protein comes from both the endothelial cells and the platelets. Thus the
platelet protein content could mask any changes in the endothelial cell protein that may
occur during sepsis. Since ascorbate did not affect P-selectin expression on either the
mRNA or protein level, we must conclude that the protective effect of ascorbate (i.e.,
reduction in adhesion) is independent of changes in the overall P-selectin levels.

4.4.1 Methodological limitations
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In the present study, treatment of cultured endothelial cells with P-selectin blocking
antibody (but not with control IgG) prevented platelet adhesion to these cells. Together
with observed P-selectin mRNA expression in these cells, the effect of blocking strongly
indicated that these cells expressed P-selectin protein. However, our inability to detect Pselectin surface protein in these cells by immunocytochemistry and flow cytometry and
the total P-selectin protein by immunoblotting pointed to a limitation of the cell culture
model (Figure 4.8). In the platelet adhesion assay, we counted about 5 - 20 adhering
platelets in each microscopic field of view including about 180 endothelial cells. This
implies that only a low percentage of endothelial cells presented P-selectin at their
surface to “capture” platelets for adhesion, after excess of platelets was subjected to coincubation with the confluent endothelial monolayer. To explain this low percentage, we
speculate that the culturing conditions reduced the number of cells expressing P-selectin
protein and/or the level of this expression per cell. This level could have been too low to
be detected by immunocytochemistry or immunoblot. The skeletal muscle vascular bed
could also have a low P-selectin expression. This low expression has been reported for
liver sinusoids (8, 40). Regarding detection of P-selectin surface expression by flow
cytometry, this limitation would be further worsened by the procedural steps necessary
for cell preparation. Detachment of cells from dishes, suspension and fixing of cells could
all negatively affect the presence of this protein at the cell surface.
In conclusion, we used an in vitro model of sepsis in mice to demonstrate that
ascorbate (i) reduces platelet-endothelial adhesion stimulated by LPS or TNF and (ii)
lowers LPS-induced vWF granular release from endothelial cells. The ability of ascorbate
to inhibit P-selectin surface expression could be an important mechanism by which
ascorbate inhibits capillary plugging.
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Figure 4.8. P-selectin protein expression in the endothelial cell model. A) Endothelial
cells treated with LPS for 6 h were assayed for P-selectin protein expression by Western
blot. Shown is a representative blot of 6 endothelial cell lines originating from 6 mice. Pselectin was not detected in the endothelial cells. Platelet lysate was used as a positive
control. B) Endothelial cells treated with LPS for 1 h were assayed for surface P-selectin
protein expression by immunocytochemistry. A FITC conjugated anti-P-selectin antibody
was co-incubated with the cells (Clone: Wug.9 at 1:100 for 1 h). No staining was
observed. Treatment of isolated platelets with the antibody was used a positive control.
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Chapter 5

SUMMARY, DISCUSSION, and FUTURE DIRECTIONS

5.1

THESIS SUMMARY

One of the key characteristics of sepsis is the cessation of capillary blood flow that leads
to tissue hypoxia and possibly multiple organ dysfunction. The mechanism behind the
cessation of flow is currently unclear. A possible mechanism is physical hindrance of the
flow due to the formation of microthrombi in the septic capillary. The coagulation system
has been known to be involved the pathophysiology of sepsis; a reduced platelet count in
blood is a particularly telling index of the severity of sepsis. Thus, I hypothesized that
increased platelet adhesion, aggregation and microthrombi formation during sepsis leads
to plugging of capillaries resulting in cessation of blood flow. This hypothesis was
addressed in Chapter 2.
Treatment with ascorbate prevented and rescued the capillary blood flow
impairment and increased survival in our animal model of sepsis. However, the means by
which ascorbate provides the beneficial effects are unknown. The effect of ascorbate is
eNOS dependent, therefore locally produced NO could be involved in the protective
effect of ascorbate. NO is a known platelet inhibitor and thus may modulate the
formation of microthrombi in the septic capillary. I hypothesized that ascorbate lowers
platelet aggregation and adhesion by decreasing P-selectin expression, thus improving
capillary blood flow during sepsis. This has been addressed in Chapters 3 and 4.
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In Chapter 2, I show that removal of platelets from the circulation significantly
reduced the capillary blood flow impairment in septic mice. Next, I observed that platelet
adhesion to the capillary wall and fibrin deposition in capillaries are increased during
sepsis. Septic capillaries also showed an increased thrombogenic potential. Finally,
administration of the general anticoagulant antithrombin, the platelet anti-aggregatory
agent eptifibatide, and an antibody that blocks P-selectin (platelet and endothelial
adhesion molecule) reduced the capillary blood flow impairment in septic mice. These
data support our hypothesis that increased microthrombi formation leads to the capillary
blood flow impairment.
Platelet adhesion in septic capillaries was decreased by an intravenous bolus of
ascorbate administered after before the onset of sepsis or later when the cessation of
capillary blood flow was already established. Also, platelet adhesion was reduced in
gp91phox knockout mice suggesting that ascorbate works by its antioxidant properties.
This effect, however, was not seen in eNOS knockout mice. Thus, similar to the capillary
blood flow impairment, reduction in platelet adhesion by ascorbate during sepsis is eNOS
dependent. Furthermore, I showed that topical application of BH4 and the NO-donor
SNAP reduced platelet adhesion in wild type septic mouse capillaries but only SNAP
reduced adhesion in eNOS-/- mice. Therefore, I proposed that ascorbate works by
restoring eNOS function through increasing BH4 availability (via preventing or reversing
oxidative alterations to BH4), leading to local NO production that reduces platelet
adhesion.
Although ascorbate reduces platelet adhesion in vivo, this decrease in platelet
adhesion could be a result of the other beneficial effects of ascorbate (i.e., increase blood
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pressure) restoring capillary blood flow. Thus, I wanted to take a closer look at platelet
adhesion and aggregation independent of flow and other in vivo parameters. Platelet
aggregation was first examined in Chapter 3. Here, I showed that LPS, TNF, or septic
plasma do not initiate platelet aggregation nor platelet P-selectin surface expression (a
marker of platelet activation). Thus, I developed our ex vivo model, using thrombin,
ADP, and thromboxane as the stimulating agents, because the concentration of these
molecules in blood is known to be increased during sepsis. I showed that ascorbate
reduced platelet aggregation initiated by these factors. Furthermore, ascorbate reduced
the sensitivity of platelet P-selectin surface expression induced by thrombin by
effectively increasing the EC50 of the dose-response curve from 0.26 to 0.40 units/ml.
Ascorbate reduction of thrombin-induced aggregation or P-selectin surface expression
was independent of platelet NOS activity as LNAME (non specific NOS inhibitor)
treatment had no effect. We concluded that ascorbate directly inhibits platelet aggregation
by reducing P-selectin surface expression. However, this reduction of platelet aggregation
alone may be insufficient to improve capillary blood flow during sepsis.
Finally, I examined platelet-endothelial adhesion in Chapter 4. Primarily, I
focused on the effect of ascorbate on this adhesion. To this end, I developed an in vitro
system to model the septic platelet-endothelium interactions. Here, I show that LPS or
TNF increased platelet-endothelial adhesion similar to the increased adhesion in the
septic capillary. Moreover, I demonstrated that ascorbate treatment prevented the increase
in adhesion caused by LPS or TNF, indicating that ascorbate can directly affect plateletendothelial adhesion. To further investigate how ascorbate prevents this adhesion, we
focused on the role of endothelial cell P-selectin expression. LPS or TNF increased P-

132
selectin mRNA expression, however ascorbate treatment had no effect on this increase
expression. By using vWF release as a marker for granule secretion from endothelial
cells, I potentially showed that LPS increased granule secretion and thus P-selectin
surface expression. Ascorbate treatment prevented the LPS-induced increase in vWF
release suggesting a potential mechanism by which ascorbate reduces platelet adhesion
caused by LPS. Finally, I showed that septic muscle tissue has increased P-selectin
mRNA expression but that ascorbate treatment does not affect this increase.
In conclusion, the sepsis-induced capillary impairment is, in part, due to the
formation of platelet-fibrin microthrombi. Ascorbate reduces the impairment by
decreasing platelet adhesion and aggregation via a reduction in P-selectin surface
expression (Figure 5.1).
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Figure 5.1. The effect of ascorbate on platelet-endothelial function in septic
capillaries. Ascorbate can directly reduce platelet aggregation and P-selectin surface
expression (i.e., platelet activation). Furthermore, ascorbate could restore local NO
production via eNOS. The local NO may further reduce platelet aggregation and
endothelial P-selectin surface expression. The summation of these effects leads to
reduced platelet adhesion and aggregation in the septic capillary leading to restoration of
blood flow.
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5.2

GENERAL DISCUSSION

5.2.1 Comparing the in vivo, ex vivo, and in vitro models of sepsis
Sepsis is a complex inflammatory disease that involves numerous cell types and
mediators. In addition, sepsis can be confounded by pre-existing diseases, making it very
difficult to study (29). The studies presented in this thesis use in vivo, ex vivo, and in vitro
models to investigate the effect of sepsis on capillary platelet-endothelial and plateletplatelet interactions. These models are used to gain insights on how ascorbate treatment
benefits capillary flow during sepsis. Capillary impairment in the mouse extensor
digitorum longus (EDL) muscle, platelet-platelet interactions of isolated platelets, and
platelet interactions with mouse microvascular endothelial cells were used as in vivo, ex
vivo, and in vitro models of sepsis, respectively. These models have both advantages and
limitations.

5.2.1.1 Mouse models of sepsis
There are several animal models used to study the mechanisms governing the
pathophysiology of sepsis. The goal of these models is to best mimic the pathogenesis
observed in septic patients. The most commonly used models are (i) direct administration
of endotoxin or viable bacteria into the animal and (ii) causing peritonitis by disrupting
the barrier of the gastrointestinal tract by cecal ligation and puncture (CLP) or direct
administration of fecal material into the peritoneum (FIP).
Endotoxemic models usually involve bolus injections of lipopolysaccharide
(LPS), a component of the wall of Gram-negative bacteria. This model is used primarily
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for its ease in standardizing the experimental conditions (22). The major criticism of this
model is its lack of clinical relevance, as the LPS challenge does not have the focus of
infection seen in clinical sepsis, because LPS levels are usually low in human patients
(7). Furthermore, the LPS model does not account for the septic cases that involve Grampositive bacteria (41).
The bacteremia model of sepsis involves the injection of cultures of viable
bacteria (16) and thus may be more clinically relevant than the endotoxemic model.
However, the injected bacteria are usually not able to replicate within the host because
they are destroyed by the immune system (13). This results in an endotoxemic model
rather than an infectious model causing the model to suffer from the same criticisms as
the LPS model. Both of these models lead to many of the clinical characteristics of sepsis
(hypotension, multiple organ dysfunction) but tend to have more acute and intense
increases in inflammatory mediators than seen in septic patients (22).
Both the FIP and CLP models of sepsis are better associated with clinical sepsis.
As well as having a peritoneal focus of infection and displaying the characteristic
symptoms of clinical sepsis, both models produce a continuous and sustained production
of cytokines similar to human patients (21, 22, 59). For the present series of
investigations, the FIP model was used over the CLP because it is a more standardized
model. The resulting infection due to CLP can vary greatly depending on the amount of
fecal material that leaks into the peritoneum. Thus the precision in replicating the surgical
procedure is essential for accurate data. The FIP model eliminates this factor by
standardizing the amount of feces injected into the peritoneum. Also, the sham control
animals for the FIP model receive an intraperitoneal injection of saline as opposed to a
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sham surgery in the CLP model, which itself leads to the release of inflammatory
cytokines and thus confound the outcome of bacterial infection. When comparing the FIP
and CLP models, the major drawback for the FIP model compared to the CLP model is
that it is less clinically relevant as clinical septic patients have varied degrees of
infections.

5.2.1.2 Methodological limitations to the models
In Chapter 2, mouse EDL muscle was observed by intravital microscopy. Although
skeletal muscle is not a critical organ, it is used to model capillary beds because the
capillaries can be easily visualized microscopically when compared to other organs that
move (e.g., lungs, heart). Moreover, the EDL muscle was chosen because it can be
surgically exposed without disturbance to the muscle and because it has evenly
distributed parallel capillaries. Also, it is possible to visualize platelets in these capillaries
in real time. I used the epi-illuminated EDL muscle preparation where scattered light is
reflected from the muscle surface to the microscope objective, thus limiting the optical
resolution at a higher magnification. Therefore, platelets (about 1 μm diameter) needed to
be labelled with a fluorescence dye to be visualized under fluorescent illumination. The
labelling makes it difficult to distinguish between single platelets and small aggregates of
4 or less platelets. Furthermore, labelling of the platelets requires administering the dye
just before the visualization (e.g., 6 h into sepsis when cessation of flow in capillaries has
already occurred). Thus, any platelets situated in capillaries that are completely plugged
(and therefore, have no flow) would not be labelled by the dye. This causes an
underestimate in the reported platelet adhesion in septic capillaries.
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Because ascorbate may have many effects in vivo, the reduction in platelet
adhesion in the capillaries after ascorbate administration could be a result of these other
effects (e.g., increased blood pressure to restore flow) as oppose to the direct effect
ascorbate may have on platelet-endothelial interactions. To this end, we employed ex vivo
and in vitro models to eliminate the complexities of the in vivo model. I used isolated
platelets in the ex vivo model to measure platelet function under septic conditions. One
disadvantage of this model was that LPS or TNF treatments, which represent the
initiating and inflammatory cytokine stages of sepsis, respectively, did not produce any
platelet activation. Therefore, to mimic the septic condition, the stimulating agents
thrombin, ADP, and thromboxane A2 were used instead. Another limitation to the ex vivo
model is that the conditions in the aggregation assay are pro-aggregatory (i.e., platelets
aggregate spontaneously when left in the cuvette for longer than 1 - 2 h), thus
diminishing the potential full inhibitory effect of ascorbate I have investigated.
The final model used is an in vitro model using mouse microvascular endothelial
cells to investigate platelet-endothelial interactions. Although there was an increase in
platelet adhesion after treatment with LPS or TNF, the overall number of adhering
platelets was very low in comparison to the total number of platelets used in the assay
(i.e., ~ 0.1 % platelets adhered out of the total number of platelets applied to the
endothelial monolayer). Pilot experiments with higher concentrations of LPS, TNF, or
thrombin failed to increase the platelet adhesion greater than that observed. It is proposed
that culturing the endothelial cells reduces in their ability to interact with platelets. This is
further evident when examining P-selectin expression in these cells. P-selectin protein
was not detected in the cells using western blot, immunocytochemistry, and flow
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cytometry techniques. However, P-selectin mRNA was present and blocking of P-selectin
reduced platelet-endothelial adhesion (Figures 4.3, 4.1) indicating the presence of Pselectin in the cells. If P-selectin was expressed in very low amounts or only present in a
small number of the cells, then this would account for the relative low adhesion seen in
this model.

5.2.2 Mechanism of capillary blood flow impairment during sepsis
The impairment of capillary blood flow during sepsis was first discovered and defined in
skeletal muscle almost 20 years ago (36). Since then it has been seen in other organs as
well as in septic patients (4, 6). Essentially, the impairment is cessation of blood flow in
approximately 50% of septic capillaries (61). The underlying pathophysiological
processes that prevent the flow of blood in these septic capillaries are yet to be fully
elucidated. Table 1.1 summarizes some of the possible processes that may contribute to
the cessation of flow.
The blood flow in capillaries can be visualized by the intravital microscopy in
terms of the movement of RBCs situated in these capillaries. Any process that prevents
RBCs from this movement will contribute to the impairment seen in sepsis. This includes
sepsis-induced changes in blood pressure or changes in the ability of the RBC to deform
to progress through the vessel. Changes in the perfusion pressure across the capillary bed
include both a decrease in arteriolar pressure at the capillary entrance as well as an
increase in venular pressure (drainage pressure) at the capillary exit (2, 5, 28). Although a
large enough decrease in arterial blood pressure could prevent flow in a capillary,
Boczkowski et al (5) showed that decreases in mean arterial pressure due to haemorrhage
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did not cause a dysfunction in capillary blood flow seen in LPS-treated rats. Venular
pressure is also increased in sepsis (28), and could potentially inhibit flow through a
capillary. However, I have observed directly with intravital microscopy a septic capillary
bed supplied by a single arteriole and drained by a single venule. Here about 50 % of
capillaries had stopped flow, while both the arteriole and the venule remained perfused
with blood (Chapter 2). Thus, capillary plugging does not require stoppage of blood in
the arteriole or the venule.
Even though blood pressure changes in the capillaries are unlikely to result in
capillary blood flow impairment, they could combine with other processes in the septic
microvasculature (e.g., increased wall permeability) to contribute to capillary flow
stoppage. Edema and vascular leak are key features of sepsis that promote swelling of the
tissue surrounding the capillaries (37). If the swelling becomes severe enough, the
resulting decrease in the capillary diameter could potentially inhibit the passage of RBCs
in the capillary. A similar situation could occur due to the swelling of endothelial cells,
another event that occurs during sepsis (26). Blood flow could also be stopped by
blocking the passage of RBCs by physical means such as adhering non-deformable
RBCs, adhering WBCs, or microthrombi. RBCs have been shown to become adhesive to
LPS treated endothelial cells (19) and stiffen in during sepsis (3). Leukocyte adhesion is
markedly increased during sepsis (12, 45, 55). However, this event is usually measured in
post-capillary venules and therefore the contribution of leukocytes to the capillary
plugging is unclear. Due to the targeting of leukocytes to specific organs during sepsis
(47), the role in the cessation of capillary blood flow by WBCs is organ-dependent.
Roller et al (55) observed increase leukocyte trapping in lung capillaries in a mouse CLP
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model, and Croner et al (12) showed increased leukocyte adhesion in liver sinusoids in a
rat CLP model. On the other hand, in our skeletal muscle model I did not notice any
significant increase in leukocytes in septic capillaries (Chapter 2). I showed an increase in
platelet adhesion and fibrin disposition in septic capillaries in our mouse FIP model
(Figure 2.1). These 2 factors combined suggest the presence of microthrombi in the
capillaries that could prevent blood flow. I further showed that removal of platelets or
inhibition of thrombi formation reduces the number of stopped-flow capillaries in septic
mice (Chapter 2).
Overall, the stoppage of blood flow that defines the capillary blood flow
impairment is most likely caused by a combination of these factors (for example, a single
platelet adhering to the endothelium may not itself block flow but might reduce the
capillary diameter enough that a stiffened RBC cannot fit through). The interventions that
I used in Chapter 2 to reduce microthrombi formation did not reduce the capillary blood
flow impairment back to sham levels. This indicates that, in addition to microthrombi
formation, other mechanism(s) are contributing to the observed impairment.

5.2.3 Capillary plugging in septic skeletal muscle
As mentioned in section 5.2.2, there are 3 main cell types that can be involved in
impeding capillary blood flow: leukocytes, RBCs, and platelets clumped in
microthrombi. Since leukocyte involvement in the skeletal muscle in minimal, our
skeletal muscle model allowed addressing the impact of only the 2 cell types (platelets
and RBCs) on the capillary plugging.
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5.2.3.1 Microthrombi formation
The exact size, shape, and composition of a microthrombus necessary to plug a capillary
are not known. Single adhering platelets are not large enough to prevent the blood flow
alone. I have observed that platelet adhesion and fibrin deposition is increased in the
septic capillary and that they both usually occur in the same capillary. However due to
limitations in our methodology I cannot accurately determine (i) the size (number of
platelets) per aggregate, (ii) the architecture of fibrin depositions, and (iii) the relative
contribution of platelets and fibrin to the microthrombi. I observed that septic conditions
promote both platelet aggregation and platelet-endothelial adhesion (Chapters 3 and 4).
This adhesion contributes to the microthrombi formation in the septic capillary. However,
the role of fibrin in the plugging of septic capillary has not been studied.
Although fibrin has other roles, its primary function is to support clot formation and
provide integrity to the thrombi (66, 68). In the septic capillaries I observed the fibrin
depositions as long strands as opposed to clumps (Figure 5.2). From these observations I
cannot rule out that, after fibrin is formed (by cleavage of fibrinogen), whether it remains
in the plasma or it lines the vessels without participating in clot formation (thus not
contributing to the plugging of the capillaries). Fibrin deposition has also been observed
in capillaries of endotoxemic rat liver and kidney but not in the lung (60), further
indicating that the mechanism of capillary plugging is organ specific. This study used
immunohistochemistry techniques, which like our study only indicates that fibrin is
present. The specific role and necessity of fibrin in the capillary plugging in sepsis will
need to be further investigated to completely understand its role in capillary impairment.
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Figure 5.2. Image of fibrin plaques in septic capillaries. Fibrin plaques (white arrows)
were visualized with fluorescence illumination using Alexa 488-labelled anti-fibrin
antibody, injected i.v. 10 min prior visualization (antibody does not bind to fibrinogen).
Plaques were seen only in capillaries with stationary red blood cells (black arrows).
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5.2.3.2 RBC adhesion
In a sepsis-like state, RBCs are activated, causing red blood cell adhesion in vitro (18,
19). Adhering RBCs may contribute to the microthrombus formation and could
potentially plug capillaries. Under septic conditions, RBCs are known to express
phosphatidylserine (PS) on their surface (33). In view of the emerging evidence of
endothelial cells expressing a PS binding receptor (57), this suggests a possible
mechanism for RBC-EC adhesion that may contribute to the capillary plugging.
Furthermore, PS will bind to thrombospondin, which will also bind to the vitronectin
receptor on endothelial cells suggesting another role for PS expression on RBCs to
participate in RBC-endothelium adhesion (24). I have observed RBCs in plugged
capillaries; however, thus far, I was unable to determine whether they contribute to
capillary stoppage or they are simply just caught behind the blockage. I conducted pilot
studies in our lab using an in vitro approach (RBCs flowed over ECs in a parallel plate
system). In these pilots, I did not visualize any obvious increase in RBC adhesion under
septic conditions (LPS or TNF treatment of ECs). Due to methodological difficulties
and lack of any meaningful observations, further studies here were not pursued.

5.2.4 Ascorbate and capillary blood flow impairment during sepsis
It has been shown that an intravenous bolus of ascorbate prevents and reverses the sepsisinduced capillary blood flow impairment (2, 61, 62, Chapter 2). Although we have made
progress in understanding the capillary blood flow impairment on the tissue level (i.e.,
oxidative stress and eNOS dysfunction contribute to the impairment) and in
understanding how ascorbate inhibits impairment at this level (i.e., it reduces oxidative
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stress and restores eNOS function), the potential mechanisms of how ascorbate achieves
this inhibition at the cellular/molecular level are still poorly understood. In Figures 2.4
and 2.5, I show that ascorbate reduces platelet adhesion in the septic capillary, which
suggests that ascorbate reduces the capillary plugging by preventing microthrombi
formation. Overall, it is very likely that ascorbate reduces the capillary blood flow
impairment by more than one mechanism.
Ascorbate may reduce capillary plugging by affecting platelets, RBCs, and
leukocytes. Data in this thesis indicate that ascorbate decreases platelet adhesion and
aggregation under septic conditions through a reduction in P-selectin surface expression.
Ascorbate may also reduce RBC adhesion by decreasing PS exposure on RBCs.
Ascorbate reduces PS exposure in RBCs in an apoptotic model (40). Reduced PS
exposure prevents RBC adhesion by lowering its exposure to its counter receptors
(described in section 5.2.3). Finally, ascorbate may reduce capillary plugging by lowering
leukocyte adhesion. Ascorbic acid can reduce in vitro leukocyte adhesion to endothelial
cells (15). Also, vitamin C can reduce in vivo leukocyte adhesion in diabetic and oxidized
LDL models of oxidative stress (32, 38). Although the effect of ascorbate on leukocyte
adhesion would only have a minor beneficial effect on capillary blood flow in skeletal
muscle, this effect could be very important in other organs.
Ascorbate reduces the permeability of LPS-stimulated endothelial monolayers
(25) and therefore it may reduce endothelial swelling during sepsis. There is evidence
that antioxidants decrease endothelial swelling in an ischemia/reperfusion model (64).
Also, antioxidants have been shown to decrease edema in lung and heart tissues in animal
models of sepsis (34, 58, 69). Furthermore, the antioxidant tirilazad can reduced RBC
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stiffness in an animal stress model (8). Thus, ascorbate may increase capillary diameter
and RBC deformability to prevent the RBCs from getting stuck in the capillaries.
Ascorbate may influence the capillary blood flow during sepsis indirectly, since it
prevents the drop in mean arterial blood pressure seen in CLP rats (62). Ascorbate
improves arteriolar function by inhibiting the sepsis-reduced conducted vasoconstriction
in mouse arterioles (46) and by reversing arterial hyporesponsiveness to vasoconstrictors
in human patients injected with LPS (53).

5.2.5 The protective effect of ascorbate and eNOS
Our lab has shown that the protective effect of ascorbate on the sepsis-induced
impairment of capillary blood flow is eNOS dependent (61). Figure 2.5 shows that
ascorbate’s inhibitory effect on platelet adhesion in septic capillaries is also eNOS
dependent. However, using the ex vivo approach, the reduction in platelet aggregation by
ascorbate was NOS independent suggesting that ascorbate reduces aggregation directly.
This reduction in aggregation must be insufficient to improve capillary blood flow in
septic capillaries without eNOS function (Chapter 3).
The NO derived from eNOS maintains vascular homeostatisis by regulating
vasomotor tone (51), inhibiting platelet aggregation (1), inhibiting leukocyte-endothelium
adhesion (35), and inhibiting apoptosis (9). NO acts directly on guanylyl cyclase to
produce cGMP that activates downstream target protein kinase G. This pathway mediates
vascular smooth muscle relaxation and platelet inhibition. NO may also modulate protein
function by nitrosylation of thiol residues in the amino acid sequence. One example is the
nitrosylation of N-ethylmaleimide-sensitive factor (NSF), a protein critical for proper
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granule docking with the plasma membrane. Nitrosylated NSF has reduced function
resulting in reduced granule secretion (43).
In vivo, ascorbate prevents and reverses the oxidation of BH4 and thus restores
proper eNOS function (Figure 1.2). The local NO can then participate in the unplugging
of capillaries by reducing platelet adhesion and aggregation. In the ex vivo model, platelet
aggregation was reduced by ascorbate, independent of platelet derived NO. I proposed
that endothelial derived NO may further inhibit both platelet aggregation and P-selectin
surface expression (Chapter 3). Thus restoration of endothelial eNOS function may be
required for ascorbate’s full anti-platelet effects in vivo. Data in Chapter 4 suggest that
ascorbate reduces platelet-endothelial adhesion by at least 2 mechanisms. One of these
mechanisms could be reduced surface P-selectin protein expression on endothelial cells
due to nitrosylation of NSF. It would be interesting to know whether the effect of
ascorbate on LPS or TNF-induced platelet-endothelial cell adhesion in vitro is NOS
dependent since LPS and TNF increase adhesion by different mechanisms (and NO
could play a different role in each case).

5.2.6 Ascorbate as a treatment for sepsis
The data in the thesis suggest a major role of the coagulation system in the
pathophysiology of sepsis. Specifically, Figure 2.2 shows that inhibition of coagulation
by antithrombin or eptifibatide prevents or reverses the capillary blood flow impairment
respectively. This indicates that targeting the coagulation pathway would be of interest
for treating septic patients. However, clinical trials with anticoagulants have not been
successful in improving survival (14).
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Ascorbate in combination with vitamin E was shown to decrease mortality in
critically ill patients (11) as well as reduce multiple organ failure in critically ill surgical
patients (49). Although the above studies have indicated a beneficial affect of ascorbate,
the administration of ascorbate alone has not yet being used as a therapy for septic
patients.
A recent trial involving critically ill patients by Heyland et al (27) showed no
improvement in 28-day mortality with antioxidant treatment. However, the treatment in
this study was a mixture of antioxidants given orally as oppose to just ascorbate given
intravenously as presented in this thesis. It is possible that reduction of platelet adhesion
and restoration of capillary blood flow could have negative consequences on survival.
Platelet adhesion to neutrophils is necessary for the formation of neutrophil extracellular
traps that have a role in bacteria trapping (10). Restored blood flow may promote
spreading of the infection. Thus, a negative effect of ascorbate treatment could be
prolonging the infection.
Ascorbate may be more beneficial than other antioxidants because it is readily
absorbed into microvascular endothelial cells and platelets through high affinity vitamin
C transporters (67). This leads to the accumulation of high levels of intracellular
ascorbate (up to 16 mM in endothelial cells and greater than 1mM in platelets (44, 67).
Furthermore, excess ascorbate is quickly excreted (over 4 - 5 h) through the kidneys (50).
This is beneficial because ROS are required as a defense mechanism against infections
(including bactericidal effects and the up-regulation on inflammatory cytokines).
Removal of ROS may be the reason that other antioxidants have not always offered
protective results in septic patients (17). Moreover, mice with a major source of ROS
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genetically removed (gp91phox knockouts, a subunit of NADPH oxidase) have reduced
24 h survival in a FIP model of sepsis when compared with wild type mice (unpublished
observations from our lab). Thus, complete suppression and/or continuous antioxidant
therapy in septic patients could be detrimental. Ascorbate being quickly absorbed or
excreted would reduce the effect of this possible complication.
Septic patients have reduced plasma ascorbate levels (23). High doses of
ascorbate are needed to restore plasma ascorbate levels in critically ill patients back to
control (39, 49, 56). There is no evidence to suggest toxic effects of high dose ascorbate
on organ function. In healthy volunteers, intravenous injections of 7.5 g, 33 mg/kg, or 2 g
of ascorbate induced no pro-oxidant changes in plasma markers of oxidative stress (48),
no abnormalities in blood cell counts, or liver or kidney function (42), and did not alter
superoxide production by neutrophils (20), respectively.

5.2.7 Overall implications of this research
Sepsis leads to the cessation of capillary blood flow which results in tissue hypoxia and
potentially multiple organ failure (36, 61). The cellular mechanisms that cause this
impairment have yet to be fully determined. Furthermore, treatment of septic animals
with ascorbate has shown to prevent and reverse the cessation in capillary blood flow (2,
61, 62). Again, the mechanisms underlying ascorbate’s beneficial effects are not
completely clear.
The research in this thesis is the first to demonstrate the participation of the
coagulation system in the capillary blood flow impairment during sepsis. In particular, we
show increased platelet adhesion and fibrin deposition in septic capillaries suggesting the
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presence of microthrombi in the capillaries. The increase in platelet adhesion is reduced
by ascorbate eNOS-dependently similar to the improvement of capillary blood flow by
ascorbate. This demonstrates another mechanism by which ascorbate could improve the
outcome in sepsis.
Ascorbate reduces platelet aggregation and platelet-endothelial adhesion in ex
vivo and in vitro models of sepsis, respectively; by a reduction in the cell surface Pselectin protein expression. The reduced aggregation and adhesion by ascorbate leads to a
decrease in the formation of microthrombi in the capillaries. Removal of microthrombi
leads to the rescue of capillary blood flow, attenuating tissue hypoxia. This thesis
demonstrates a mechanism of ascorbate providing a beneficial effect during sepsis and
thus supports investigations of the use of ascorbate as an adjuvant treatment for septic
patients.

5.3

FUTURE DIRECTIONS

5.3.1 Effect of eNOS inhibition on platelet adhesion, in vitro
As mentioned previously, the protective effects of ascorbate against the impairment of
capillary blood flow and increase platelet adhesion to the capillary wall during sepsis is
eNOS dependent. In Chapter 4, I show that ascorbate can reduce LPS-induce plateletendothelial adhesion by reducing P-selectin surface expression as assayed by vWF
granule expression. I propose that ascorbate acts to restore eNOS function similar to our
in vivo model. The NO produced by restored eNOS may nitrosylate NSF, causing a
reduction in granule secretion, and thus reduce surface P-selectin protein expression (43).
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Furthermore, ascorbate is expected to reduce TNF-induced platelet-endothelial adhesion
by a different mechanism since TNF does not cause an increase in granule secretion.
Investigating the effect of NOS inhibition in the in vitro model of LPS-induced plateletendothelial adhesion should clarify the mechanism of ascorbate’s inhibitory effect.

5.3.2 Mechanism of ascorbate inhibition of TNF-induced platelet
adhesion, in vitro
TNF caused an increase in platelet-endothelial adhesion in our in vitro model. However,
this increase was not due to increased P-selectin protein expression on the endothelial cell
surface. Blockade of P-selectin prevented this increase in adhesion indicating the
increased adhesion still involved P-selectin. Ascorbate reduced the platelet adhesion
through a mechanism that did not include reduction in granule secretion. It has been
suggested that ascorbate could affect the protein kinase C (PKC) pathway in platelets
(Chapter 3), but this pathway has not been examined in endothelial cells. TNF is known
to increase the activity of the transcription factor nuclear factor B (NFB) through a
PKC pathway (54). NFB up-regulates inflammatory cytokines and numerous genes that
regulate cell adhesion including P-selectin (52), E-selectin (65), vascular cell adhesion
molecule (VCAM)-1 (30), and intercellular adhesion molecule (ICAM)-1 (63).
Moreover, PKC has been shown to modulate the function of platelet-endothelial cell
adhesion molecule (PECAM)-1 (31), which has the potential to facilitate the adhesion of
platelets to the endothelial cells in our model. The role of PKC in TNF-induced platelet
adhesion in our in vitro model could be examined by pharmacological inhibition of PKC
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by calphostin C. PKC activity assays in platelets and endothelial cells could be used to
determine if ascorbate alters PKC function.
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